{"ticker": {"uuid": "8c654ed5-801b-4414-9f18-cbf5c9a3fc80", "symbol": "GRAL", "name": "GRAIL, LLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "GRAIL Inc Revenue Breakdown \u2013 LSX:A40F8M", "summary": "GRAIL Inc (LSX:A40F8M) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top-performing \"Screening\" segment, an increase from 104.93 million EUR in the previous year. The United States was the largest geographical contributor, accounting for 116.72 million EUR in revenue.", "url": "https://www.tradingview.com/symbols/LSX-A40F8M/financials-segments", "source_link": "https://www.tradingview.com/symbols/LSX-A40F8M/financials-segments", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-08T18:40:29", "published_display": "08 Aug 2026 18:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.046282, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 48.2, "age_days": 5.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date?", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Is+GRAIL+%28GRAL%29+Fairly+Valued+Following+Galleri+Adoption+Growth+And+The+FDA+Panel+Date%3F%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-08-08T05:12:00+00:00", "published_display": "08 Aug 2026 05:12", "source_kind": "aggregator", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006512, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 13.3, "age_days": 5.8, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026", "summary": "Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made false and misleading statements regarding the success likelihood of its NHS-Galleri trial, leading to a significant stock price drop after the company announced its primary endpoint was not met. Investors who purchased GRAL stock between May 13, 2024, and February 19, 2026, and suffered losses are encouraged to contact the firm.", "url": "https://www.eagletribune.com/region/class-action-deadline-tonight-faruqi-faruqi-llp-reminds-grail-gral-investors-of-securities-class-action/article_b0b1e8d6-65ef-5c46-bde4-04a7b232a91e.html", "source_link": "https://www.eagletribune.com/region/class-action-deadline-tonight-faruqi-faruqi-llp-reminds-grail-gral-investors-of-securities-class-action/article_b0b1e8d6-65ef-5c46-bde4-04a7b232a91e.html", "source_link_is_lookup": false, "source_name": "Eagle-Tribune", "published_at": "2026-08-04T18:41:03", "published_display": "04 Aug 2026 18:41", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.179732, "evidence_share": 6.7, "evidence_share_display": "6.7", "freshness_pct": 40.0, "age_days": 9.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors", "summary": "The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Grail, Inc. (NASDAQ: GRAL) who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial, specifically concerning the sufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the firm to discuss their legal rights.", "url": "https://www.globenewswire.com/news-release/2026/08/04/3338452/0/en/portnoy-law-firm-announces-class-action-on-behalf-of-grail-inc-investors.html", "source_link": "https://www.globenewswire.com/news-release/2026/08/04/3338452/0/en/portnoy-law-firm-announces-class-action-on-behalf-of-grail-inc-investors.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-08-04T13:41:03", "published_display": "04 Aug 2026 13:41", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.132764, "evidence_share": 4.9, "evidence_share_display": "4.9", "freshness_pct": 39.1, "age_days": 9.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit", "summary": "Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the NHS-Galleri cancer screening trial's design and efficacy, particularly concerning the sufficiency of its three-year follow-up period. GRAIL's stock plummeted by 50.55% on February 19, 2026, after the company disclosed that the trial failed to meet its primary endpoint and admitted to a flawed timeline, leading to over $2.2 billion in market cap loss.", "url": "https://www.prnewswire.com/news-releases/gral-deadline-today-grail-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302841801.html", "source_link": "https://www.prnewswire.com/news-releases/gral-deadline-today-grail-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302841801.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-08-04T09:41:03", "published_display": "04 Aug 2026 09:41", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 10, "tone_signals": ["Failed To Meet", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.174098, "evidence_share": 6.5, "evidence_share_display": "6.5", "freshness_pct": 38.5, "age_days": 9.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Financial Markets", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "$GRAL Securities: Suffer Losses on Your GRAIL, Inc.", "summary": "Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50% stock drop after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to contact BFA Law before the August 4, 2026, lead plaintiff deadline.", "url": "https://www.globenewswire.com/news-release/2026/07/31/3336696/0/en/GRAL-Securities-Suffer-Losses-on-Your-GRAIL-Inc-Investment-BFA-Law-Reminds-Investors-of-the-Securities-Fraud-Lawsuit-to-Recover-Losses.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/31/3336696/0/en/GRAL-Securities-Suffer-Losses-on-Your-GRAIL-Inc-Investment-BFA-Law-Reminds-Investors-of-the-Securities-Fraud-Lawsuit-to-Recover-Losses.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-31T06:46:00", "published_display": "31 Jul 2026 06:46", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 10, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.148043, "evidence_share": 5.5, "evidence_share_display": "5.5", "freshness_pct": 25.6, "age_days": 13.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference", "summary": "GRAIL (Nasdaq: GRAL) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through GRAIL's investor relations website, with the replay archived for at least 30 days. This event provides investors with an opportunity to learn more about GRAIL's mission to detect cancer early.", "url": "https://www.stocktitan.net/news/GRAL/grail-to-present-at-the-canaccord-genuity-46th-annual-growth-v5g4s9wswmxc.html", "source_link": "https://www.stocktitan.net/news/GRAL/grail-to-present-at-the-canaccord-genuity-46th-annual-growth-v5g4s9wswmxc.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-30T20:10:10", "published_display": "30 Jul 2026 20:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000455, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.7, "age_days": 14.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights", "summary": "Rosen Law Firm is notifying stockholders of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit for alleged misleading statements made between May 13, 2025, and February 19, 2026. The lawsuit claims GRAIL concealed material adverse facts regarding its NHS-Galleri trial's sufficiency to demonstrate a reduction in Stage III-IV cancers. Shareholders have until August 4, 2026, to file as lead plaintiff.", "url": "https://www.businesswire.com/news/home/20260730189315/en/GRAL-Deadline-Rosen-Law-Firm-Urges-GRAIL-Inc.-NASDAQ-GRAL-Stockholders-to-Contact-the-Firm-for-Information-About-Their-Rights", "source_link": "https://www.businesswire.com/news/home/20260730189315/en/GRAL-Deadline-Rosen-Law-Firm-Urges-GRAIL-Inc.-NASDAQ-GRAL-Stockholders-to-Contact-the-Firm-for-Information-About-Their-Rights", "source_link_is_lookup": false, "source_name": "Business Wire", "published_at": "2026-07-30T17:10:10", "published_display": "30 Jul 2026 17:10", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.082093, "evidence_share": 3.0, "evidence_share_display": "3", "freshness_pct": 24.2, "age_days": 14.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm", "summary": "Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in Grail\u2019s NHS-Galleri trial, thereby harming investors. Investors who purchased Grail securities between May 13, 2025, and February 19, 2026, are encouraged to join the class action, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/30/3336260/9788/en/bronstein-gewirtz-grossman-llc-urges-grail-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/30/3336260/9788/en/bronstein-gewirtz-grossman-llc-urges-grail-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-30T16:10:10", "published_display": "30 Jul 2026 16:10", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.081755, "evidence_share": 3.0, "evidence_share_display": "3", "freshness_pct": 24.1, "age_days": 14.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld crucial internal data suggesting the NHS-Galleri trial's three-year design was insufficient to achieve its primary endpoint, leading to a significant stock price drop when the trial failed. Investors who suffered losses are encouraged to contact the firm to recover damages.", "url": "https://www.morningstar.com/news/pr-newswire/20260729ny14467/levi-korsinsky-reminds-grail-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-4-2026-gral", "source_link": "https://www.morningstar.com/news/pr-newswire/20260729ny14467/levi-korsinsky-reminds-grail-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-4-2026-gral", "source_link_is_lookup": false, "source_name": "Morningstar", "published_at": "2026-07-30T11:11:18", "published_display": "30 Jul 2026 11:11", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.145156, "evidence_share": 5.4, "evidence_share_display": "5.4", "freshness_pct": 23.6, "age_days": 14.6, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL to Announce Second Quarter 2026 Financial Results", "summary": "GRAIL, Inc. (Nasdaq: GRAL) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. Interested parties can find a link to the live webcast and recorded replay on the investor relations section of GRAIL's website.", "url": "https://www.tradingview.com/news/prnewswire:4e7787a30514b:0", "source_link": "https://www.tradingview.com/news/prnewswire:4e7787a30514b:0", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-29T23:39:38", "published_display": "29 Jul 2026 23:39", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.011909, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 12.4, "age_days": 15.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol", "summary": "Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for allegedly making false and misleading statements regarding its NHS Galleri trial. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the firm by August 4, 2026, to discuss potentially becoming lead plaintiff. The lawsuit claims GRAIL concealed issues with the trial's ability to demonstrate a reduction in Stage III-IV cancers, leading to a significant stock price drop after negative trial results were revealed on February 19, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/29/3335669/0/en/Bragar-Eagel-Squire-P-C-Reminds-GRAIL-Inc-Investors-They-Have-Until-August-4th-to-Contact-the-Firm-Seeking-Lead-Plaintiff-Rol.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/29/3335669/0/en/Bragar-Eagel-Squire-P-C-Reminds-GRAIL-Inc-Investors-They-Have-Until-August-4th-to-Contact-the-Firm-Seeking-Lead-Plaintiff-Rol.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-29T22:09:49", "published_display": "29 Jul 2026 22:09", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.114075, "evidence_share": 4.2, "evidence_share_display": "4.2", "freshness_pct": 22.4, "age_days": 15.1, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL webcast on Aug. 5 results open to all interested parties", "summary": "GRAIL (Nasdaq: GRAL) will announce its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. The live webcast and recorded replay will be accessible via the investor relations section of GRAIL's website, and interested participants are encouraged to register in advance.", "url": "https://www.stocktitan.net/news/GRAL/grail-to-announce-second-quarter-2026-financial-l0rwltc0vzrt.html", "source_link": "https://www.stocktitan.net/news/GRAL/grail-to-announce-second-quarter-2026-financial-l0rwltc0vzrt.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-29T20:11:58", "published_display": "29 Jul 2026 20:11", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.011673, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 12.2, "age_days": 15.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Court Deadline: GRAIL, Inc. Investor Deadline in Securities Fraud Class Action is August 4 \u2013 Contact BFA Law if You Lost Money", "summary": "Bleichmar Fonti & Auld LLP has announced a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which caused a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who lost money are encouraged to contact BFA Law by the lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/29/3335031/0/en/GRAL-Court-Deadline-GRAIL-Inc-Investor-Deadline-in-Securities-Fraud-Class-Action-is-August-4-Contact-BFA-Law-if-You-Lost-Money.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/29/3335031/0/en/GRAL-Court-Deadline-GRAIL-Inc-Investor-Deadline-in-Securities-Fraud-Class-Action-is-August-4-Contact-BFA-Law-if-You-Lost-Money.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-29T10:17:20", "published_display": "29 Jul 2026 10:17", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 12, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.120317, "evidence_share": 4.5, "evidence_share_display": "4.5", "freshness_pct": 21.3, "age_days": 15.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "BlackRock (GRAL holder) discloses 7.9% GRAIL, Inc. stake in 13G/A", "summary": "BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.9% passive ownership stake in GRAIL, Inc. (GRAL). This ownership amounts to 3,376,085 shares of GRAIL common stock, with BlackRock holding sole voting power over 3,312,474 shares and sole dispositive power over all 3,376,085 shares. The filing indicates that no single client of BlackRock exceeds five percent of GRAIL's outstanding common shares.", "url": "https://www.stocktitan.net/sec-filings/GRAL/schedule-13g-a-grail-inc-amended-passive-investment-disclosure-9cc48304b59c.html", "source_link": "https://www.stocktitan.net/sec-filings/GRAL/schedule-13g-a-grail-inc-amended-passive-investment-disclosure-9cc48304b59c.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-28T21:41:39", "published_display": "28 Jul 2026 21:41", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.017939, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 20.2, "age_days": 16.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors", "summary": "The Portnoy Law Firm has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated materially false and misleading statements regarding its NHS-Galleri trial, concealing that the trial design was insufficient to demonstrate a reduction in Stage III-IV cancers within the specified follow-up period. Investors have until August 4, 2026, to file a lead plaintiff motion.", "url": "https://www.mycarrollcountynews.com/online_features/press_releases/article_8f4a60ee-cb5f-5bce-a8d2-c6461c19b171.html", "source_link": "https://www.mycarrollcountynews.com/online_features/press_releases/article_8f4a60ee-cb5f-5bce-a8d2-c6461c19b171.html", "source_link_is_lookup": false, "source_name": "Carroll County Mirror-Democrat", "published_at": "2026-07-28T15:41:39", "published_display": "28 Jul 2026 15:41", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.05906, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 19.7, "age_days": 16.4, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Lost Money on GRAIL, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm", "summary": "The Gross Law Firm has issued a notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025, and February 19, 2026. The firm encourages these shareholders to join a class action lawsuit seeking recovery, stating that the company allegedly provided false and misleading statements regarding its NHS-Galleri trial's potential to reduce Stage III-IV cancers. Following the announcement that the trial's primary endpoint was not met, GRAIL's stock price dramatically declined by over 50% in one day.", "url": "https://www.prnewswire.com/news-releases/lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery---contact-the-gross-law-firm-302836210.html", "source_link": "https://www.prnewswire.com/news-releases/lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery---contact-the-gross-law-firm-302836210.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-28T13:41:39", "published_display": "28 Jul 2026 13:41", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Legal or regulatory risk"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000361, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.3, "age_days": 16.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Pomerantz LLP Shares Class Action Details With Investors in GRAIL, Inc. \u2013 GRAL", "summary": "Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) following a significant drop in its stock price. The lawsuit stems from Grail's announcement on February 19, 2026, that its NHS-Galleri Trial did not meet its primary endpoint, leading to a more than 50% decline in stock value. Investors who purchased Grail securities during the Class Period have until August 4, 2026, to seek appointment as Lead Plaintiff.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-shares-class-action-details-with-investors-in-grai-1175891", "source_link": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-shares-class-action-details-with-investors-in-grai-1175891", "source_link_is_lookup": false, "source_name": "ACCESS Newswire", "published_at": "2026-07-28T07:40:58", "published_display": "28 Jul 2026 07:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 44, "tone_signals": ["Legal victory", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.039502, "evidence_share": 1.5, "evidence_share_display": "1.5", "freshness_pct": 19.1, "age_days": 16.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action \u2013 GRAL", "summary": "Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements and/or concealed material adverse facts regarding its NHS-Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the Rosen Law Firm to join the class action and potentially recover damages.", "url": "https://wahanariau.com/amp/48907/gral-deadline-alert-rosen-a-global-and-leading-law-firm-encourages-grail-inc-investors-to-secure-counsel-before-important-august-4-deadline-in-securities-class-action-%E2%80%93-gral", "source_link": "https://wahanariau.com/amp/48907/gral-deadline-alert-rosen-a-global-and-leading-law-firm-encourages-grail-inc-investors-to-secure-counsel-before-important-august-4-deadline-in-securities-class-action-%E2%80%93-gral", "source_link_is_lookup": false, "source_name": "wahanariau.com", "published_at": "2026-07-27T22:50:21", "published_display": "27 Jul 2026 22:50", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.055093, "evidence_share": 2.0, "evidence_share_display": "2", "freshness_pct": 18.4, "age_days": 17.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "$GRAL Lawsuit Notice: BFA Law Reminds GRAIL, Inc. Investors", "summary": "BFA Law has filed a securities fraud class action lawsuit against GRAIL, Inc. following a 50% stock drop. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial by making positive statements about the trial's design and results, despite the three-year timeframe being insufficient to demonstrate the primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case.", "url": "https://www.globenewswire.com/news-release/2026/07/27/3333411/0/en/gral-lawsuit-notice-bfa-law-reminds-grail-inc-investors-of-august-4-lead-plaintiff-deadline-after-50-stock-drop-triggers-securities-fraud-class-action.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/27/3333411/0/en/gral-lawsuit-notice-bfa-law-reminds-grail-inc-investors-of-august-4-lead-plaintiff-deadline-after-50-stock-drop-triggers-securities-fraud-class-action.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-27T11:40:22", "published_display": "27 Jul 2026 11:40", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Legal victory", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.031513, "evidence_share": 1.2, "evidence_share_display": "1.2", "freshness_pct": 17.6, "age_days": 17.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "AUGUST 4, 2026 GRAL DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit", "summary": "Robbins Geller Rudman & Dowd LLP announces a shareholder class action lawsuit against GRAIL, Inc. and its executives for alleged Securities Exchange Act violations. The lawsuit claims that Grail made false and misleading statements regarding its NHS-Galleri trial's primary endpoint, which was not achieved, leading to a significant stock price drop. Investors who suffered substantial losses between", "url": "https://www.newsfilecorp.com/release/306507/AUGUST-4-2026-GRAL-DEADLINE-GRAIL-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Shareholder-Class-Action-Lawsuit?lang=fr", "source_link": "https://www.newsfilecorp.com/release/306507/AUGUST-4-2026-GRAL-DEADLINE-GRAIL-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Shareholder-Class-Action-Lawsuit?lang=fr", "source_link_is_lookup": false, "source_name": "TMX Newsfile", "published_at": "2026-07-27T10:40:58", "published_display": "27 Jul 2026 10:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 13, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.082055, "evidence_share": 3.0, "evidence_share_display": "3", "freshness_pct": 17.5, "age_days": 17.6, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, Inc. ($GRAL) Investors Notified of August 4 Court Deadline in Securities Fraud Lawsuit Over Trial Results Allegations", "summary": "A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and its executives for securities fraud, stemming from a significant stock drop after the NHS-Galleri cancer trial failed to meet its primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case, which alleges the company made misleading statements about the trial's design and results. The lawsuit claims GRAIL's stock fell over 50% following the announcement that the trial did not show a statistically significant reduction in late-stage cancers.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/grail-inc.-gral-investors-notified-of-august-4-court-deadline-in-1195458", "source_link": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/grail-inc.-gral-investors-notified-of-august-4-court-deadline-in-1195458", "source_link_is_lookup": false, "source_name": "ACCESS Newswire", "published_at": "2026-07-27T03:40:12", "published_display": "27 Jul 2026 03:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 12, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.084742, "evidence_share": 3.1, "evidence_share_display": "3.1", "freshness_pct": 17.0, "age_days": 17.9, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL Inc Revenue Breakdown \u2013 HAN:NL0", "summary": "GRAIL Inc (NL0) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top segment, Screening, showing an increase from the previous year's 104.93 million EUR. The United States was the largest contributor to the company's revenue, accounting for 116.72 million EUR.", "url": "https://www.tradingview.com/symbols/HAN-NL0/financials-segments", "source_link": "https://www.tradingview.com/symbols/HAN-NL0/financials-segments", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-24T22:41:40", "published_display": "24 Jul 2026 22:41", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003713, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 6.2, "age_days": 20.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail", "summary": "Priority Health has partnered with Color Health and Grail to introduce two new cancer support solutions for self-funded employers. These solutions, available from January 1, 2027, will offer virtual cancer navigation, support, and multi-cancer early detection to Priority Health's 1.4 million members. The aim is to proactively address cancer earlier, provide personalized support, and potentially reduce healthcare costs associated with late-stage diagnoses.", "url": "https://medcitynews.com/2026/07/priority-health-launches-2-cancer-support-solutions-with-color-health-grail", "source_link": "https://medcitynews.com/2026/07/priority-health-launches-2-cancer-support-solutions-with-color-health-grail", "source_link_is_lookup": false, "source_name": "MedCity News", "published_at": "2026-07-24T17:41:40", "published_display": "24 Jul 2026 17:41", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 7.6e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 20.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Shareholder Alert: GRAIL, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm", "summary": "The Gross Law Firm has issued a shareholder alert for investors of GRAIL, Inc. (GRAL), announcing a securities class action lawsuit. Investors who purchased GRAL shares between May 13, 2020, and February 19, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment. The lawsuit alleges that GRAIL defendants made misleading statements and concealed adverse facts about the company's NHS-Galleri trial results, leading to a significant stock price drop.", "url": "https://www.lincolnjournal.com/online_features/press_releases/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit---investors-should-contact-the/article_94708ee2-d16a-587d-a4c1-0d423f4e6816.html", "source_link": "https://www.lincolnjournal.com/online_features/press_releases/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit---investors-should-contact-the/article_94708ee2-d16a-587d-a4c1-0d423f4e6816.html", "source_link_is_lookup": false, "source_name": "lincolnjournal.com", "published_at": "2026-07-24T17:12:52", "published_display": "24 Jul 2026 17:12", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 16, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.056683, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 13.4, "age_days": 20.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline", "summary": "Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) following a significant stock price drop. The lawsuit alleges that GRAIL and its executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, specifically regarding a three-year follow-up period that proved insufficient. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and incurred substantial losses, have until August 4, 2026, to seek lead plaintiff status.", "url": "https://www.prnewswire.com/news-releases/hagens-berman-sobol-shapiro-llp-alert-grail-inc-nasdaq-gral-investors-urged-to-contact-hagens-berman-securities-fraud-class-action-filed-august-4-2026-lead-plaintiff-deadline-302833795.html", "source_link": "https://www.prnewswire.com/news-releases/hagens-berman-sobol-shapiro-llp-alert-grail-inc-nasdaq-gral-investors-urged-to-contact-hagens-berman-securities-fraud-class-action-filed-august-4-2026-lead-plaintiff-deadline-302833795.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-24T12:12:52", "published_display": "24 Jul 2026 12:12", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 44, "tone_signals": ["Legal victory", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030696, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 13.1, "age_days": 20.5, "influence_label": "Low", "duplicate_count": 3, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results \u2013 Investors Notified to Contact BFA Law", "summary": "A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) due to a 50% stock dive following allegations that the company misrepresented results from its NHS-Galleri cancer trial. The lawsuit claims GRAIL misled investors regarding the trial's effectiveness and its ability to achieve its primary endpoint of reducing late-stage cancers within the stated three-year timeframe. Investors are encouraged to contact BFA Law to discuss their legal options, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/24/3332754/0/en/GRAL-Fraud-Notification-GRAIL-Inc-Sued-for-Fraud-Over-Misrepresentations-about-its-Trial-Results-Investors-Notified-to-Contact-BFA-Law.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/24/3332754/0/en/GRAL-Fraud-Notification-GRAIL-Inc-Sued-for-Fraud-Over-Misrepresentations-about-its-Trial-Results-Investors-Notified-to-Contact-BFA-Law.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-24T10:12:52", "published_display": "24 Jul 2026 10:12", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.044037, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 13.0, "age_days": 20.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "How Grail Inc Com (GRAL) Affects Rotational Strategy Timing", "summary": "The article analyzes Grail Inc Com (GRAL) through a quantitative research lens, highlighting weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies resistance levels and an exceptional short setup with significant downside potential against low risk. Several institutional trading strategies, including position, momentum, and risk hedging, are detailed along with multi-timeframe signal analysis to guide investors.", "url": "https://news.stocktradersdaily.com/news_release/89/How_Grail_Inc_Com_GRAL_Affects_Rotational_Strategy_Timing_072426030603_1784876763.html", "source_link": "https://news.stocktradersdaily.com/news_release/89/How_Grail_Inc_Com_GRAL_Affects_Rotational_Strategy_Timing_072426030603_1784876763.html", "source_link_is_lookup": false, "source_name": "Stock Traders Daily", "published_at": "2026-07-24T03:10:37", "published_display": "24 Jul 2026 03:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 37, "tone_signals": ["Negative financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.020447, "evidence_share": 0.8, "evidence_share_display": "0.8", "freshness_pct": 12.6, "age_days": 20.9, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026", "summary": "Faruqi & Faruqi, LLP reminds investors of a securities class action lawsuit against Grail, Inc. (GRAL) with a lead plaintiff deadline of August 4, 2026. The lawsuit alleges that Grail made misleading statements regarding the success of its NHS-Galleri cancer detection trial, which resulted in a significant stock price drop. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the law firm.", "url": "https://natlawreview.com/press-releases/gral-investor-deadline-approaching-faruqi-faruqi-llp-reminds-grail-gral", "source_link": "https://natlawreview.com/press-releases/gral-investor-deadline-approaching-faruqi-faruqi-llp-reminds-grail-gral", "source_link_is_lookup": false, "source_name": "The National Law Review", "published_at": "2026-07-24T01:10:37", "published_display": "24 Jul 2026 01:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.056261, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 12.5, "age_days": 21.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm", "summary": "Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, thereby harming investors who purchased securities between May 13, 2025, and February 19, 2026. Investors are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/23/3332410/9788/en/bronstein-gewirtz-grossman-llc-urges-grail-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/23/3332410/9788/en/bronstein-gewirtz-grossman-llc-urges-grail-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-23T16:09:10", "published_display": "23 Jul 2026 16:09", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 21, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.04584, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 12.1, "age_days": 21.4, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact SueWallSt", "summary": "SueWallSt is announcing a securities class action lawsuit against Grail, Inc. (GRAL) on behalf of shareholders who experienced significant losses after the company's NHS-Galleri trial failed to meet its primary endpoint. Investors are encouraged to seek lead plaintiff status by August 4, 2026, though class members can still participate in a settlement even if they miss this deadline. The lawsuit alleges that Grail made misleading statements about the trial's progress and expected outcomes, leading to a 50.55% stock drop when the failure was disclosed.", "url": "https://www.tradingview.com/news/prnewswire:460c025b04926:0-lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery-contact-suewallst", "source_link": "https://www.tradingview.com/news/prnewswire:460c025b04926:0-lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery-contact-suewallst", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-23T14:10:37", "published_display": "23 Jul 2026 14:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 13, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.058531, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 12.0, "age_days": 21.5, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against GRAIL, Inc. (GRAL)", "summary": "Bernstein Liebhard LLP has announced a securities class action lawsuit filed against GRAIL, Inc. on behalf of investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements, leading to artificially inflated stock prices and significant losses for investors. Shareholders are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/23/3332262/0/en/shareholder-alert-bernstein-liebhard-llp-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-grail-inc-gral.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/23/3332262/0/en/shareholder-alert-bernstein-liebhard-llp-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-grail-inc-gral.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-23T13:10:37", "published_display": "23 Jul 2026 13:10", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 15, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.052286, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 11.9, "age_days": 21.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026", "summary": "Bernstein Liebhard LLP reminds investors of GRAIL, Inc. (NASDAQ: GRAL) that they have until August 4, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, causing investors to suffer losses. Investors who purchased shares during this period and wish to serve as lead plaintiff must file papers by the deadline.", "url": "https://www.globenewswire.com/news-release/2026/07/22/3331458/0/en/GRAIL-INC-INVESTORS-WITH-LOSSES-HAVE-UNTIL-AUGUST-4-2026-TO-JOIN-SECURITIES-CLASS-ACTION-Bernstein-Liebhard-LLP-Announces-Deadline.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/22/3331458/0/en/GRAIL-INC-INVESTORS-WITH-LOSSES-HAVE-UNTIL-AUGUST-4-2026-TO-JOIN-SECURITIES-CLASS-ACTION-Bernstein-Liebhard-LLP-Announces-Deadline.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-22T13:42:10", "published_display": "22 Jul 2026 13:42", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 18, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.044599, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 10.8, "age_days": 22.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Deadline Alert: Levi & Korsinsky Reminds Grail, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026", "summary": "Levi & Korsinsky reminds investors of Grail, Inc. (NASDAQ: GRAL) that the deadline to apply for lead plaintiff in a securities class action lawsuit is August 4, 2026. This lawsuit follows a significant stock drop after Grail's NHS-Galleri trial failed its primary endpoint, resulting in losses of over 50% for investors who purchased securities between May 13, 2025, and February 19, 2026. The firm encourages affected shareholders to contact them to evaluate their eligibility to recover losses or serve as a lead plaintiff.", "url": "https://www.morningstar.com/news/pr-newswire/20260722ny09414/gral-deadline-alert-levi-korsinsky-reminds-grail-inc-gral-investors-of-securities-class-action-deadline-on-august-4-2026", "source_link": "https://www.morningstar.com/news/pr-newswire/20260722ny09414/gral-deadline-alert-levi-korsinsky-reminds-grail-inc-gral-investors-of-securities-class-action-deadline-on-august-4-2026", "source_link_is_lookup": false, "source_name": "Morningstar", "published_at": "2026-07-22T13:42:10", "published_display": "22 Jul 2026 13:42", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.066421, "evidence_share": 2.5, "evidence_share_display": "2.5", "freshness_pct": 10.8, "age_days": 22.5, "influence_label": "Low", "duplicate_count": 5, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman", "summary": "Hagens Berman is investigating GRAIL, Inc. (NASDAQ: GRAL) for alleged securities law violations in connection with its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL misled investors about the trial's design and efficacy, particularly regarding the adequacy of the three-year follow-up period, leading to a significant stock drop after the trial failed its primary endpoint. Investors who suffered substantial losses are encouraged to come forward and have until August 4, 2026, to seek lead plaintiff status.", "url": "https://www.prnewswire.com/news-releases/investor-notice-grail-inc-gral-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-hagens-berman-302831217.html", "source_link": "https://www.prnewswire.com/news-releases/investor-notice-grail-inc-gral-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-hagens-berman-302831217.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-21T20:11:49", "published_display": "21 Jul 2026 20:11", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 16, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.048322, "evidence_share": 1.8, "evidence_share_display": "1.8", "freshness_pct": 10.1, "age_days": 23.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors", "summary": "The Portnoy Law Firm has announced a class action lawsuit on behalf of investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated false and misleading statements about the NHS-Galleri trial, concealing that the trial period was insufficient to achieve its primary endpoint of reducing Stage III-IV cancers. Investors have until August 4, 2026, to file a lead plaintiff motion.", "url": "https://www.wboc.com/online_features/press_releases/portnoy-law-firm-announces-class-action-on-behalf-of-grail-inc-investors/article_3ea64be0-b68b-5693-9f52-aeaa7c8a1868.html", "source_link": "https://www.wboc.com/online_features/press_releases/portnoy-law-firm-announces-class-action-on-behalf-of-grail-inc-investors/article_3ea64be0-b68b-5693-9f52-aeaa7c8a1868.html", "source_link_is_lookup": false, "source_name": "WBOC TV", "published_at": "2026-07-21T14:10:19", "published_display": "21 Jul 2026 14:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024004, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 9.8, "age_days": 23.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Enterprise value to EBIT forward of GRAIL, Inc. \u2013 NASDAQ:GRAL", "summary": "This article from TradingView provides a financial metric for GRAIL, Inc. (NASDAQ: GRAL), specifically its enterprise value to EBIT (Earnings Before Interest and Taxes) forward. The content is primarily a title and navigational elements, indicating the company's listing on the Nasdaq Stock Market under the Health Technology sector. The presented information is limited to the company name and the financial metric.", "url": "https://www.tradingview.com/symbols/NASDAQ-GRAL/financials-statistics-and-ratios/enterprise-value-ebit-fwd", "source_link": "https://www.tradingview.com/symbols/NASDAQ-GRAL/financials-statistics-and-ratios/enterprise-value-ebit-fwd", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-21T11:10:19", "published_display": "21 Jul 2026 11:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003655, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 3.8, "age_days": 23.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences", "Earnings"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Lawsuit Notice: $GRAL Legal News: GRAIL, Inc. Trial Results and 50% Stock Drop Trigger Securities Fraud Class Action", "summary": "Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who purchased GRAIL stock are encouraged to contact the law firm to learn about their legal options, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.prnewswire.com/news-releases/lawsuit-notice-gral-legal-news-grail-inc-trial-results-and-50-stock-drop-trigger-securities-fraud-class-action-302830328.html", "source_link": "https://www.prnewswire.com/news-releases/lawsuit-notice-gral-legal-news-grail-inc-trial-results-and-50-stock-drop-trigger-securities-fraud-class-action-302830328.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-21T10:10:19", "published_display": "21 Jul 2026 10:10", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 12, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.054461, "evidence_share": 2.0, "evidence_share_display": "2", "freshness_pct": 9.6, "age_days": 23.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit", "summary": "Glancy Prongay Wolke & Rotter LLP reminds investors of Grail, Inc. (GRAL) about an upcoming August 4, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that Grail made misleading statements during the Class Period of May 13, 2025, to February 19, 2026, regarding its NHS-Galleri Trial, after which the stock price dropped significantly. Investors who suffered losses are encouraged to contact the firm to inquire about pursuing claims.", "url": "https://www.globenewswire.com/news-release/2026/07/20/3330049/0/en/deadline-alert-grail-inc-gral-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3330049/0/en/deadline-alert-grail-inc-gral-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-21T08:11:49", "published_display": "21 Jul 2026 08:11", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 16, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.045988, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 9.6, "age_days": 23.7, "influence_label": "Low", "duplicate_count": 3, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Role", "summary": "Bragar Eagel & Squire, P.C. has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false or misleading statements regarding its NHS Galleri trial, specifically concerning the insufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors have until August 4, 2026, to apply to be appointed as lead plaintiff.", "url": "https://www.globenewswire.com/news-release/2026/07/20/3330153/0/en/bragar-eagel-squire-p-c-reminds-grail-inc-investors-they-have-until-august-4th-to-contact-the-firm-seeking-lead-plaintiff-role.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3330153/0/en/bragar-eagel-squire-p-c-reminds-grail-inc-investors-they-have-until-august-4th-to-contact-the-firm-seeking-lead-plaintiff-role.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-20T22:09:42", "published_display": "20 Jul 2026 22:09", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.031132, "evidence_share": 1.2, "evidence_share_display": "1.2", "freshness_pct": 9.2, "age_days": 24.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP has issued a shareholder alert for Grail, Inc. (NASDAQ: GRAL) investors, announcing a securities class action lawsuit. The lawsuit alleges that Grail misled investors regarding its NHS-Galleri trial, which was projected to achieve a statistically significant reduction in late-stage cancers but failed to meet its primary endpoint, causing a 50.55% stock drop. Investors who purchased shares during the Class Period (May 13, 2025, through February 19, 2026) are encouraged to contact the law firm to learn about recovering their losses.", "url": "https://www.globenewswire.com/news-release/2026/07/20/3329863/3080/en/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit-investors-should-contact-levi-korsinsky.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3329863/3080/en/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit-investors-should-contact-levi-korsinsky.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-20T14:40:55", "published_display": "20 Jul 2026 14:40", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 9, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.051901, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 8.9, "age_days": 24.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS", "summary": "Hagens Berman is investigating a securities class action against GRAIL, Inc. (GRAL) following a $2.2 billion market cap wipeout after its NHS-Galleri cancer screening trial failed to meet its primary endpoint. The lawsuit alleges that GRAIL misled investors by concealing insufficient trial design and withholding critical data regarding the efficacy and timeline of the study. Investors who suffered losses between May 13, 2025, and Feb. 19, 2026, are encouraged to come forward by the lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/20/3329814/0/en/GRAIL-Inc-GRAL-Faces-Securities-Class-Action-Amid-NHS-Galleri-Trial-Failure-2-2B-Market-Cap-Wipeout-HBSS.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3329814/0/en/GRAIL-Inc-GRAL-Faces-Securities-Class-Action-Amid-NHS-Galleri-Trial-Failure-2-2B-Market-Cap-Wipeout-HBSS.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-20T09:44:00", "published_display": "20 Jul 2026 09:44", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Failed To Meet", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.043672, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 8.7, "age_days": 24.6, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GRAIL, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and certain officers. The lawsuit claims that defendants made misleading statements between May 13, 2025, and February 19, 2026, regarding the likelihood of success in Grail's NHS-Galleri trial. Investors who suffered losses are encouraged to join the case and have until August 4, 2026, to request to be appointed as lead plaintiff.", "url": "https://natlawreview.com/press-releases/gral-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-grail-1", "source_link": "https://natlawreview.com/press-releases/gral-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-grail-1", "source_link_is_lookup": false, "source_name": "The National Law Review", "published_at": "2026-07-19T05:09:56", "published_display": "19 Jul 2026 05:09", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 15, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030037, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 7.8, "age_days": 25.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, Inc. Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit", "summary": "The Rosen Law Firm reminds purchasers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, that they have an opportunity to lead a securities fraud class action lawsuit. Investors who bought GRAIL common stock during this period can seek compensation without upfront fees, and the deadline to move the Court to serve as lead plaintiff is August 4, 2026. The lawsuit alleges that GRAIL provided misleading positive statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial results, causing damages to investors.", "url": "https://www.keybiscayneportal.com/online_features/press_releases/grail-inc-deadline-gral-investors-have-opportunity-to-lead-grail-inc-securities-fraud-lawsuit/article_45b5e25f-fd6d-5c0c-b976-ab2e92d1e6cf.html", "source_link": "https://www.keybiscayneportal.com/online_features/press_releases/grail-inc-deadline-gral-investors-have-opportunity-to-lead-grail-inc-securities-fraud-lawsuit/article_45b5e25f-fd6d-5c0c-b976-ab2e92d1e6cf.html", "source_link_is_lookup": false, "source_name": "Key Biscayne Portal", "published_at": "2026-07-18T19:40:55", "published_display": "18 Jul 2026 19:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 33, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.018777, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 7.5, "age_days": 26.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, INC. DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL,", "summary": "The Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial's sufficiency in demonstrating cancer reduction. Investors are encouraged to secure counsel to pursue potential compensation.", "url": "https://www.globenewswire.com/news-release/2026/07/17/3329331/673/en/GRAIL-INC-DEADLINE-ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-GRAIL-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-GRAL.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/17/3329331/673/en/GRAIL-INC-DEADLINE-ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-GRAIL-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-GRAL.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-17T23:40:22", "published_display": "17 Jul 2026 23:40", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023276, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 6.9, "age_days": 27.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL INVESTOR DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit", "summary": "Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against GRAIL, Inc. for alleged violations of the Securities Exchange Act of 1934. Investors who purchased GRAL common stock between May 13, 2025, and February 19, 2026, and suffered substantial losses, have until August 4, 2026, to seek appointment as lead plaintiff. The lawsuit claims Grail made misleading statements regarding its NHS-Galleri trial's primary endpoint, which ultimately failed to show a statistically significant reduction in late-stage cancers.", "url": "https://www.newsfilecorp.com/release/304848/GRAL-INVESTOR-DEADLINE-GRAIL-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit?lang=fr", "source_link": "https://www.newsfilecorp.com/release/304848/GRAL-INVESTOR-DEADLINE-GRAIL-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit?lang=fr", "source_link_is_lookup": false, "source_name": "TMX Newsfile", "published_at": "2026-07-17T19:50:00", "published_display": "17 Jul 2026 19:50", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 15, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.026178, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 6.8, "age_days": 27.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Director at GRAIL, Inc. (GRAL) receives 427 deferred stock units in fee swap", "summary": "GRAIL, Inc. Director Gregory L. Summe was granted 427 deferred stock units (DSUs) as compensation, valued at $31,787.67, in lieu of cash director fees. The DSUs, priced at $74.36 per unit, vested immediately on July 15, 2026, and increased his direct holdings to 45,672 shares. This transaction was reported in a Form 4 filing and summarized by Rhea-AI.", "url": "https://www.stocktitan.net/sec-filings/GRAL/form-4-grail-inc-insider-trading-activity-578c62f55bba.html", "source_link": "https://www.stocktitan.net/sec-filings/GRAL/form-4-grail-inc-insider-trading-activity-578c62f55bba.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-16T21:11:26", "published_display": "16 Jul 2026 21:11", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001936, "evidence_share": 0.1, "evidence_share_display": "<0.1", "freshness_pct": 2.0, "age_days": 28.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, Inc. (GRAL) director receives 276 deferred stock units as fees", "summary": "GRAIL, Inc. director William J. Chase was granted 276 deferred stock units on July 15, 2026, as compensation for director fees, totaling $20,568.49. These units, priced at $74.36 per share, vested immediately, increasing his direct holdings to 42,978 shares. This transaction was reported in a Form 4 filing and represents a conversion of cash fees into equity under the company's 2024 Equity Incentive Plan.", "url": "https://www.stocktitan.net/sec-filings/GRAL/form-4-grail-inc-insider-trading-activity-555e0a9c627c.html", "source_link": "https://www.stocktitan.net/sec-filings/GRAL/form-4-grail-inc-insider-trading-activity-555e0a9c627c.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-16T21:11:26", "published_display": "16 Jul 2026 21:11", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 28.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Investor Alert: HBSS Probes GRAIL, Inc. (GRAL) Following Securities Class Action Over Failed NHS-Galleri Trial", "summary": "Hagens Berman is investigating GRAIL, Inc. (GRAL) following a class action lawsuit alleging the company misled investors about the design and efficacy of its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL concealed inadequate trial design and withheld critical data, leading to a significant stock price collapse after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to submit their claims by August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/15/3328178/32716/en/gral-investor-alert-hbss-probes-grail-inc-gral-following-securities-class-action-over-failed-nhs-galleri-trial.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/15/3328178/32716/en/gral-investor-alert-hbss-probes-grail-inc-gral-following-securities-class-action-over-failed-nhs-galleri-trial.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-16T18:11:16", "published_display": "16 Jul 2026 18:11", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 12, "tone_signals": ["Failed To Meet", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.032168, "evidence_share": 1.2, "evidence_share_display": "1.2", "freshness_pct": 6.1, "age_days": 28.3, "influence_label": "Low", "duplicate_count": 2, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs GRAIL, Inc. (GRAL) Investors of a Securities Fraud Lawsuit", "summary": "Berger Montague PC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL concealed material inadequacies in the NHS-Galleri trial design, leading to the trial's failure to achieve its primary endpoint. Following this announcement, GRAIL's stock plummeted by over 50%.", "url": "https://www.marketscreener.com/news/grail-inc-securities-fraud-notice-berger-montague-informs-grail-inc-gral-investors-of-a-secur-ce7f5ed3db8bf124", "source_link": "https://www.marketscreener.com/news/grail-inc-securities-fraud-notice-berger-montague-informs-grail-inc-gral-investors-of-a-secur-ce7f5ed3db8bf124", "source_link_is_lookup": false, "source_name": "www.marketscreener.com", "published_at": "2026-07-16T14:10:14", "published_display": "16 Jul 2026 14:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.017886, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 6.0, "age_days": 28.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL DEADLINE: SueWallSt Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline", "summary": "SueWallSt is reminding investors of Grail, Inc. (NASDAQ: GRAL) about an upcoming securities class action deadline of August 4, 2026. The lawsuit alleges that Grail's leadership withheld detailed results from the NHS-Galleri trial, leading to a 50.55% stock plunge after the trial failed to meet its primary endpoint. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and suffered losses, may be eligible to join the lawsuit.", "url": "https://www.prnewswire.com/news-releases/gral-deadline-suewallst-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline-302827273.html", "source_link": "https://www.prnewswire.com/news-releases/gral-deadline-suewallst-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline-302827273.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-16T14:10:14", "published_display": "16 Jul 2026 14:10", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 11, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.034217, "evidence_share": 1.3, "evidence_share_display": "1.3", "freshness_pct": 6.0, "age_days": 28.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri\u00ae Multi-Cancer Early Detection Blood Test to Employer Plans", "summary": "Priority Health, a leading Michigan health plan, has partnered with GRAIL to offer the Galleri multi-cancer early detection blood test to its self-insured employer groups, making it the first in Michigan to do so. This expansion follows Priority Health's earlier integration of Galleri into its Medicare Advantage plans, aiming to improve early cancer detection, reduce healthcare costs, and enhance patient outcomes by identifying cancers before symptoms appear. The Galleri test screens for over 50 cancer types with a simple blood draw, complementing existing standard-of-care screenings.", "url": "https://www.prnewswire.com/news-releases/priority-health-collaborates-with-grail-as-the-first-michigan-health-plan-to-offer-the-galleri-multi-cancer-early-detection-blood-test-to-employer-plans-302827214.html", "source_link": "https://www.prnewswire.com/news-releases/priority-health-collaborates-with-grail-as-the-first-michigan-health-plan-to-offer-the-galleri-multi-cancer-early-detection-blood-test-to-employer-plans-302827214.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-16T13:10:14", "published_display": "16 Jul 2026 13:10", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 28.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, INC. (GRAL) SHAREHOLDER ALERT Bernstein Liebhard LLP", "summary": "Bernstein Liebhard LLP has issued a shareholder alert reminding investors of GRAIL, Inc. (NASDAQ: GRAL) about an upcoming August 4, 2026 deadline for a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, leading to artificially inflated stock prices and significant losses for investors. Investors who purchased shares during this period and suffered losses are encouraged to act promptly.", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328545/0/en/grail-inc-gral-shareholder-alert-bernstein-liebhard-llp-reminds-grail-inc-investors-of-upcoming-deadline.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/16/3328545/0/en/grail-inc-gral-shareholder-alert-bernstein-liebhard-llp-reminds-grail-inc-investors-of-upcoming-deadline.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-16T13:10:14", "published_display": "16 Jul 2026 13:10", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 18, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024567, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 6.0, "age_days": 28.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) and its officers. The lawsuit alleges that GRAIL made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial between May 13, 2025, and February 19, 2026. Investors with substantial losses are encouraged to come forward by August 4, 2026, to potentially lead the class action.", "url": "https://www.natlawreview.com/press-releases/gral-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-grail-0", "source_link": "https://www.natlawreview.com/press-releases/gral-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-grail-0", "source_link_is_lookup": false, "source_name": "The National Law Review", "published_at": "2026-07-16T10:10:14", "published_display": "16 Jul 2026 10:10", "source_kind": "publisher", "company_focus": 0.86, "company_focus_pct": 86, "company_focus_label": "Company discussed", "sentiment": "negative", "sentiment_pct": 21, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.016734, "evidence_share": 0.6, "evidence_share_display": "0.6", "freshness_pct": 5.9, "age_days": 28.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP has announced a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL) for alleged misrepresentations concerning its NHS-Galleri trial. The lawsuit claims that the trial's three-year design was insufficient to achieve its primary endpoint of reducing late-stage cancers, leading to a significant stock price drop. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and incurred losses may be eligible to join the class action.", "url": "https://www.morningstar.com/news/pr-newswire/20260715ny04361/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit-investors-with-losses-may-contact-levi-korsinsky", "source_link": "https://www.morningstar.com/news/pr-newswire/20260715ny04361/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit-investors-with-losses-may-contact-levi-korsinsky", "source_link_is_lookup": false, "source_name": "Morningstar", "published_at": "2026-07-15T13:39:47", "published_display": "15 Jul 2026 13:39", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 13, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.034599, "evidence_share": 1.3, "evidence_share_display": "1.3", "freshness_pct": 5.4, "age_days": 29.5, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "$GRAL Investor Loss Alert: GRAIL, Inc. Investors may have been Misled after Channel Stuffing Claims Lead to 50% Stock Drop \u2013 Contact BFA Law if You Lost Money", "summary": "A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud after its stock dropped 50%. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which failed to meet its primary endpoint of reducing late-stage cancers. Investors who suffered losses are encouraged to contact Bleichmar Fonti & Auld LLP by August 4, 2026, to discuss their legal options.", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327542/0/en/gral-investor-loss-alert-grail-inc-investors-may-have-been-misled-after-channel-stuffing-claims-lead-to-50-stock-drop-contact-bfa-law-if-you-lost-money.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/15/3327542/0/en/gral-investor-loss-alert-grail-inc-investors-may-have-been-misled-after-channel-stuffing-claims-lead-to-50-stock-drop-contact-bfa-law-if-you-lost-money.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-15T06:17:00", "published_display": "15 Jul 2026 06:17", "source_kind": "press_release", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 20, "tone_signals": ["Failed To Meet", "Legal victory", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.026039, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 5.2, "age_days": 29.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}], "by_tier": {"direct": [{"title": "GRAIL Inc Revenue Breakdown \u2013 LSX:A40F8M", "summary": "GRAIL Inc (LSX:A40F8M) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top-performing \"Screening\" segment, an increase from 104.93 million EUR in the previous year. The United States was the largest geographical contributor, accounting for 116.72 million EUR in revenue.", "url": "https://www.tradingview.com/symbols/LSX-A40F8M/financials-segments", "source_link": "https://www.tradingview.com/symbols/LSX-A40F8M/financials-segments", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-08T18:40:29", "published_display": "08 Aug 2026 18:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "b74e2ded1d5932365ecb807771da20b46e46dc5f32011d45451bbf4963622103", "target_scope": "GRAIL Inc Revenue Breakdown \u2013 LSX:A40F8M GRAIL Inc (LSX:A40F8M) generated 125.31 million EUR in revenue last year.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.3025, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.046282, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 48.2, "age_days": 5.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date?", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Is+GRAIL+%28GRAL%29+Fairly+Valued+Following+Galleri+Adoption+Growth+And+The+FDA+Panel+Date%3F%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-08-08T05:12:00+00:00", "published_display": "08 Aug 2026 05:12", "provider": "archive", "providers": ["archive"], "provider_symbol": "", "provider_symbols": ["GRAL.ARCHIVE"], "target_provider_symbol": "GRAL.ARCHIVE", "cross_listing": false, "source_names": ["Market source"], "source_kind": "aggregator", "story_key": "2aa46d82f435f9e17378fea19e6cd6923b0e72c5a88f035323a20115bc0fc1e3", "target_scope": "Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date?", "durable_archive": true, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006512, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 13.3, "age_days": 5.8, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026", "summary": "Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made false and misleading statements regarding the success likelihood of its NHS-Galleri trial, leading to a significant stock price drop after the company announced its primary endpoint was not met. Investors who purchased GRAL stock between May 13, 2024, and February 19, 2026, and suffered losses are encouraged to contact the firm.", "url": "https://www.eagletribune.com/region/class-action-deadline-tonight-faruqi-faruqi-llp-reminds-grail-gral-investors-of-securities-class-action/article_b0b1e8d6-65ef-5c46-bde4-04a7b232a91e.html", "source_link": "https://www.eagletribune.com/region/class-action-deadline-tonight-faruqi-faruqi-llp-reminds-grail-gral-investors-of-securities-class-action/article_b0b1e8d6-65ef-5c46-bde4-04a7b232a91e.html", "source_link_is_lookup": false, "source_name": "Eagle-Tribune", "published_at": "2026-08-04T18:41:03", "published_display": "04 Aug 2026 18:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL", "GRAL.ARCHIVE"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Eagle-Tribune"], "source_kind": "publisher", "story_key": "58af1a3e1e801d0aecc09b3805f1b3324c5418b2865d10ed61098efbfcb6fccd", "target_scope": "CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026 Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made false and misleading statements regarding the success likelihood of its NHS-Galleri trial, leading to a significant stock price drop after the company announced its primary endpoint was not met. Investors who purchased GRAL stock between May 13, 2024, and February 19, 2026, and suffered losses are encouraged to contact the firm.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.786, "provider_directional_mass": 0.431, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.179732, "evidence_share": 6.7, "evidence_share_display": "6.7", "freshness_pct": 40.0, "age_days": 9.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors", "summary": "The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Grail, Inc. (NASDAQ: GRAL) who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial, specifically concerning the sufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the firm to discuss their legal rights.", "url": "https://www.globenewswire.com/news-release/2026/08/04/3338452/0/en/portnoy-law-firm-announces-class-action-on-behalf-of-grail-inc-investors.html", "source_link": "https://www.globenewswire.com/news-release/2026/08/04/3338452/0/en/portnoy-law-firm-announces-class-action-on-behalf-of-grail-inc-investors.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-08-04T13:41:03", "published_display": "04 Aug 2026 13:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "2df7c67c144d784791daa235117b2edb21b23c1ef432c5921416070a9100df6d", "target_scope": "Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Grail, Inc. (NASDAQ: GRAL) who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial, specifically concerning the sufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.408, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.132764, "evidence_share": 4.9, "evidence_share_display": "4.9", "freshness_pct": 39.1, "age_days": 9.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit", "summary": "Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the NHS-Galleri cancer screening trial's design and efficacy, particularly concerning the sufficiency of its three-year follow-up period. GRAIL's stock plummeted by 50.55% on February 19, 2026, after the company disclosed that the trial failed to meet its primary endpoint and admitted to a flawed timeline, leading to over $2.2 billion in market cap loss.", "url": "https://www.prnewswire.com/news-releases/gral-deadline-today-grail-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302841801.html", "source_link": "https://www.prnewswire.com/news-releases/gral-deadline-today-grail-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302841801.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-08-04T09:41:03", "published_display": "04 Aug 2026 09:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["PR Newswire"], "source_kind": "press_release", "story_key": "98994c996d5952bc5ee33ed116c77c00f381ac7af345734060663984c6537b99", "target_scope": "GRAL DEADLINE TODAY: GRAIL, Inc. Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the NHS-Galleri cancer screening trial's design and efficacy, particularly concerning the sufficiency of its three-year follow-up period. GRAIL's stock plummeted by 50.55% on February 19, 2026, after the company disclosed that the trial failed to meet its primary endpoint and admitted to a flawed timeline, leading to over $2.2 billion in market cap loss.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.8, "provider_directional_mass": 0.0466, "relevance_score": 0.72, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 10, "tone_signals": ["Failed To Meet", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.174098, "evidence_share": 6.5, "evidence_share_display": "6.5", "freshness_pct": 38.5, "age_days": 9.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Financial Markets", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "$GRAL Securities: Suffer Losses on Your GRAIL, Inc.", "summary": "Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50% stock drop after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to contact BFA Law before the August 4, 2026, lead plaintiff deadline.", "url": "https://www.globenewswire.com/news-release/2026/07/31/3336696/0/en/GRAL-Securities-Suffer-Losses-on-Your-GRAIL-Inc-Investment-BFA-Law-Reminds-Investors-of-the-Securities-Fraud-Lawsuit-to-Recover-Losses.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/31/3336696/0/en/GRAL-Securities-Suffer-Losses-on-Your-GRAIL-Inc-Investment-BFA-Law-Reminds-Investors-of-the-Securities-Fraud-Lawsuit-to-Recover-Losses.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-31T06:46:00", "published_display": "31 Jul 2026 06:46", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL", "GRAL.ARCHIVE"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "e1f6899c2ca207b85d5a7247f5a2120fd8881c8e704b570d2a3b4a9a0631bfa4", "target_scope": "$GRAL Securities: Suffer Losses on Your GRAIL, Inc. Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50% stock drop after the trial failed to meet its primary endpoint.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": 0.841, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 10, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.148043, "evidence_share": 5.5, "evidence_share_display": "5.5", "freshness_pct": 25.6, "age_days": 13.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference", "summary": "GRAIL (Nasdaq: GRAL) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through GRAIL's investor relations website, with the replay archived for at least 30 days. This event provides investors with an opportunity to learn more about GRAIL's mission to detect cancer early.", "url": "https://www.stocktitan.net/news/GRAL/grail-to-present-at-the-canaccord-genuity-46th-annual-growth-v5g4s9wswmxc.html", "source_link": "https://www.stocktitan.net/news/GRAL/grail-to-present-at-the-canaccord-genuity-46th-annual-growth-v5g4s9wswmxc.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-30T20:10:10", "published_display": "30 Jul 2026 20:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "a01826deaf6a0ee2fd40d3f48b458cb227cb777dcadf414c3e01bd8b63573fb3", "target_scope": "GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference GRAIL (Nasdaq: GRAL) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, at 10:00 a.m. Live and replay webcasts of the presentation will be available through GRAIL's investor relations website, with the replay archived for at least 30 days. This event provides investors with an opportunity to learn more about GRAIL's mission to detect cancer early.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.0825, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000455, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.7, "age_days": 14.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights", "summary": "Rosen Law Firm is notifying stockholders of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit for alleged misleading statements made between May 13, 2025, and February 19, 2026. The lawsuit claims GRAIL concealed material adverse facts regarding its NHS-Galleri trial's sufficiency to demonstrate a reduction in Stage III-IV cancers. Shareholders have until August 4, 2026, to file as lead plaintiff.", "url": "https://www.businesswire.com/news/home/20260730189315/en/GRAL-Deadline-Rosen-Law-Firm-Urges-GRAIL-Inc.-NASDAQ-GRAL-Stockholders-to-Contact-the-Firm-for-Information-About-Their-Rights", "source_link": "https://www.businesswire.com/news/home/20260730189315/en/GRAL-Deadline-Rosen-Law-Firm-Urges-GRAIL-Inc.-NASDAQ-GRAL-Stockholders-to-Contact-the-Firm-for-Information-About-Their-Rights", "source_link_is_lookup": false, "source_name": "Business Wire", "published_at": "2026-07-30T17:10:10", "published_display": "30 Jul 2026 17:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Business Wire"], "source_kind": "press_release", "story_key": "c8ada4eec38c2f80130ffa0f69dc4d6bfc6f212da414488bd783fc2a5d05574f", "target_scope": "GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights Rosen Law Firm is notifying stockholders of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit for alleged misleading statements made between May 13, 2025, and February 19, 2026. The lawsuit claims GRAIL concealed material adverse facts regarding its NHS-Galleri trial's sufficiency to demonstrate a reduction in Stage III-IV cancers.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.6428, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.082093, "evidence_share": 3.0, "evidence_share_display": "3", "freshness_pct": 24.2, "age_days": 14.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm", "summary": "Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in Grail\u2019s NHS-Galleri trial, thereby harming investors. Investors who purchased Grail securities between May 13, 2025, and February 19, 2026, are encouraged to join the class action, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/30/3336260/9788/en/bronstein-gewirtz-grossman-llc-urges-grail-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/30/3336260/9788/en/bronstein-gewirtz-grossman-llc-urges-grail-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-30T16:10:10", "published_display": "30 Jul 2026 16:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "e6fd327a33987eaeca3312f5bfbabe0def7bc7f024287032a9b7baea7f1e648a", "target_scope": "Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in Grail\u2019s NHS-Galleri trial, thereby harming investors. Investors who purchased Grail securities between May 13, 2025, and February 19, 2026, are encouraged to join the class action, with a lead plaintiff deadline of August 4, 2026.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.8093, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.081755, "evidence_share": 3.0, "evidence_share_display": "3", "freshness_pct": 24.1, "age_days": 14.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld crucial internal data suggesting the NHS-Galleri trial's three-year design was insufficient to achieve its primary endpoint, leading to a significant stock price drop when the trial failed. Investors who suffered losses are encouraged to contact the firm to recover damages.", "url": "https://www.morningstar.com/news/pr-newswire/20260729ny14467/levi-korsinsky-reminds-grail-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-4-2026-gral", "source_link": "https://www.morningstar.com/news/pr-newswire/20260729ny14467/levi-korsinsky-reminds-grail-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-4-2026-gral", "source_link_is_lookup": false, "source_name": "Morningstar", "published_at": "2026-07-30T11:11:18", "published_display": "30 Jul 2026 11:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Morningstar"], "source_kind": "publisher", "story_key": "824040a8c40e58bb50d0dfd33e5d3575028cb5896592170d5b0a2c3331a98cec", "target_scope": "Levi & Korsinsky Reminds Grail, Inc. Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld crucial internal data suggesting the NHS-Galleri trial's three-year design was insufficient to achieve its primary endpoint, leading to a significant stock price drop when the trial failed.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.786, "provider_directional_mass": 0.4505, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.145156, "evidence_share": 5.4, "evidence_share_display": "5.4", "freshness_pct": 23.6, "age_days": 14.6, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL to Announce Second Quarter 2026 Financial Results", "summary": "GRAIL, Inc. (Nasdaq: GRAL) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. Interested parties can find a link to the live webcast and recorded replay on the investor relations section of GRAIL's website.", "url": "https://www.tradingview.com/news/prnewswire:4e7787a30514b:0", "source_link": "https://www.tradingview.com/news/prnewswire:4e7787a30514b:0", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-29T23:39:38", "published_display": "29 Jul 2026 23:39", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "92a47c4881e711b3d2f0890ec6482282a0c8a5cf79b5b8f3b034b8160e34ca3b", "target_scope": "GRAIL to Announce Second Quarter 2026 Financial Results GRAIL, Inc. (Nasdaq: GRAL) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Interested parties can find a link to the live webcast and recorded replay on the investor relations section of GRAIL's website.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.0465, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.011909, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 12.4, "age_days": 15.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol", "summary": "Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for allegedly making false and misleading statements regarding its NHS Galleri trial. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the firm by August 4, 2026, to discuss potentially becoming lead plaintiff. The lawsuit claims GRAIL concealed issues with the trial's ability to demonstrate a reduction in Stage III-IV cancers, leading to a significant stock price drop after negative trial results were revealed on February 19, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/29/3335669/0/en/Bragar-Eagel-Squire-P-C-Reminds-GRAIL-Inc-Investors-They-Have-Until-August-4th-to-Contact-the-Firm-Seeking-Lead-Plaintiff-Rol.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/29/3335669/0/en/Bragar-Eagel-Squire-P-C-Reminds-GRAIL-Inc-Investors-They-Have-Until-August-4th-to-Contact-the-Firm-Seeking-Lead-Plaintiff-Rol.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-29T22:09:49", "published_display": "29 Jul 2026 22:09", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "a46cda258fd6388c2e70ea3bfa161975f9949f58f4fa6d8eba6d7b24ef0451b2", "target_scope": "Reminds GRAIL, Inc. has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for allegedly making false and misleading statements regarding its NHS Galleri trial. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the firm by August 4, 2026, to discuss potentially becoming lead plaintiff. The lawsuit claims GRAIL concealed issues with the trial's ability to demonstrate a reduction in Stage III-IV cancers, leading to a significant stock price drop after negative trial results were revealed on February 19, 2026.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.786, "provider_directional_mass": 0.6174, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.114075, "evidence_share": 4.2, "evidence_share_display": "4.2", "freshness_pct": 22.4, "age_days": 15.1, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL webcast on Aug. 5 results open to all interested parties", "summary": "GRAIL (Nasdaq: GRAL) will announce its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. The live webcast and recorded replay will be accessible via the investor relations section of GRAIL's website, and interested participants are encouraged to register in advance.", "url": "https://www.stocktitan.net/news/GRAL/grail-to-announce-second-quarter-2026-financial-l0rwltc0vzrt.html", "source_link": "https://www.stocktitan.net/news/GRAL/grail-to-announce-second-quarter-2026-financial-l0rwltc0vzrt.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-29T20:11:58", "published_display": "29 Jul 2026 20:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL", "GRAL.ARCHIVE"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "cd706a16b2920f20391d3039708e5a8e25b2358b96f947ab3e2736e001756c78", "target_scope": "GRAIL webcast on Aug. GRAIL (Nasdaq: GRAL) will announce its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. The live webcast and recorded replay will be accessible via the investor relations section of GRAIL's website, and interested participants are encouraged to register in advance.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.051, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.011673, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 12.2, "age_days": 15.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Court Deadline: GRAIL, Inc. Investor Deadline in Securities Fraud Class Action is August 4 \u2013 Contact BFA Law if You Lost Money", "summary": "Bleichmar Fonti & Auld LLP has announced a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which caused a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who lost money are encouraged to contact BFA Law by the lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/29/3335031/0/en/GRAL-Court-Deadline-GRAIL-Inc-Investor-Deadline-in-Securities-Fraud-Class-Action-is-August-4-Contact-BFA-Law-if-You-Lost-Money.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/29/3335031/0/en/GRAL-Court-Deadline-GRAIL-Inc-Investor-Deadline-in-Securities-Fraud-Class-Action-is-August-4-Contact-BFA-Law-if-You-Lost-Money.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-29T10:17:20", "published_display": "29 Jul 2026 10:17", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL", "GRAL.ARCHIVE"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "3939e983ef46ce66c5c061b9d1dd37ab040ff021797e66e92f41aaae9a8fa2ec", "target_scope": "GRAL Court Deadline: GRAIL, Inc. Bleichmar Fonti & Auld LLP has announced a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which caused a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": 0.4144, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 12, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.120317, "evidence_share": 4.5, "evidence_share_display": "4.5", "freshness_pct": 21.3, "age_days": 15.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "BlackRock (GRAL holder) discloses 7.9% GRAIL, Inc. stake in 13G/A", "summary": "BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.9% passive ownership stake in GRAIL, Inc. (GRAL). This ownership amounts to 3,376,085 shares of GRAIL common stock, with BlackRock holding sole voting power over 3,312,474 shares and sole dispositive power over all 3,376,085 shares. The filing indicates that no single client of BlackRock exceeds five percent of GRAIL's outstanding common shares.", "url": "https://www.stocktitan.net/sec-filings/GRAL/schedule-13g-a-grail-inc-amended-passive-investment-disclosure-9cc48304b59c.html", "source_link": "https://www.stocktitan.net/sec-filings/GRAL/schedule-13g-a-grail-inc-amended-passive-investment-disclosure-9cc48304b59c.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-28T21:41:39", "published_display": "28 Jul 2026 21:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["BLK", "GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "b6abef810e48d6713613a9fa6a8f0536e50b468a30e7d557662441f1bbdd9aae", "target_scope": "BlackRock (GRAL holder) discloses 7.9% GRAIL, Inc. has filed an amended Schedule 13G, disclosing a 7.9% passive ownership stake in GRAIL, Inc. (GRAL). This ownership amounts to 3,376,085 shares of GRAIL common stock, with BlackRock holding sole voting power over 3,312,474 shares and sole dispositive power over all 3,376,085 shares. The filing indicates that no single client of BlackRock exceeds five percent of GRAIL's outstanding common shares.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": 0.0395, "relevance_score": 0.94679, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.017939, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 20.2, "age_days": 16.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors", "summary": "The Portnoy Law Firm has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated materially false and misleading statements regarding its NHS-Galleri trial, concealing that the trial design was insufficient to demonstrate a reduction in Stage III-IV cancers within the specified follow-up period. Investors have until August 4, 2026, to file a lead plaintiff motion.", "url": "https://www.mycarrollcountynews.com/online_features/press_releases/article_8f4a60ee-cb5f-5bce-a8d2-c6461c19b171.html", "source_link": "https://www.mycarrollcountynews.com/online_features/press_releases/article_8f4a60ee-cb5f-5bce-a8d2-c6461c19b171.html", "source_link_is_lookup": false, "source_name": "Carroll County Mirror-Democrat", "published_at": "2026-07-28T15:41:39", "published_display": "28 Jul 2026 15:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Carroll County Mirror-Democrat"], "source_kind": "publisher", "story_key": "2df7c67c144d784791daa235117b2edb21b23c1ef432c5921416070a9100df6d", "target_scope": "Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. The Portnoy Law Firm has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated materially false and misleading statements regarding its NHS-Galleri trial, concealing that the trial design was insufficient to demonstrate a reduction in Stage III-IV cancers within the specified follow-up period.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.4567, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.05906, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 19.7, "age_days": 16.4, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Lost Money on GRAIL, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm", "summary": "The Gross Law Firm has issued a notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025, and February 19, 2026. The firm encourages these shareholders to join a class action lawsuit seeking recovery, stating that the company allegedly provided false and misleading statements regarding its NHS-Galleri trial's potential to reduce Stage III-IV cancers. Following the announcement that the trial's primary endpoint was not met, GRAIL's stock price dramatically declined by over 50% in one day.", "url": "https://www.prnewswire.com/news-releases/lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery---contact-the-gross-law-firm-302836210.html", "source_link": "https://www.prnewswire.com/news-releases/lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery---contact-the-gross-law-firm-302836210.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-28T13:41:39", "published_display": "28 Jul 2026 13:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["PR Newswire"], "source_kind": "press_release", "story_key": "7e8d61f4f11670dd291eea29caa33582fffdf7e9070e2a6f80265f06dad17b35", "target_scope": "Lost Money on GRAIL, Inc. (GRAL)? The Gross Law Firm has issued a notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025, and February 19, 2026. Following the announcement that the trial's primary endpoint was not met, GRAIL's stock price dramatically declined by over 50% in one day.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.577, "provider_directional_mass": 0.0025, "relevance_score": 0.72, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.473, "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Legal or regulatory risk"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000361, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.3, "age_days": 16.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Pomerantz LLP Shares Class Action Details With Investors in GRAIL, Inc. \u2013 GRAL", "summary": "Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) following a significant drop in its stock price. The lawsuit stems from Grail's announcement on February 19, 2026, that its NHS-Galleri Trial did not meet its primary endpoint, leading to a more than 50% decline in stock value. Investors who purchased Grail securities during the Class Period have until August 4, 2026, to seek appointment as Lead Plaintiff.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-shares-class-action-details-with-investors-in-grai-1175891", "source_link": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-shares-class-action-details-with-investors-in-grai-1175891", "source_link_is_lookup": false, "source_name": "ACCESS Newswire", "published_at": "2026-07-28T07:40:58", "published_display": "28 Jul 2026 07:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL", "GRAL.ARCHIVE"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["ACCESS Newswire"], "source_kind": "publisher", "story_key": "89091258ffe05abb544a4777bd3204cd080c9209087a3114b8a66a54a18979af", "target_scope": "Pomerantz LLP Shares Class Action Details With Investors in GRAIL, Inc. Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) following a significant drop in its stock price. The lawsuit stems from Grail's announcement on February 19, 2026, that its NHS-Galleri Trial did not meet its primary endpoint, leading to a more than 50% decline in stock value. Investors who purchased Grail securities during the Class Period have until August 4, 2026, to seek appointment as Lead Plaintiff.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.628, "provider_directional_mass": 0.4214, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.618, "sentiment": "negative", "sentiment_pct": 44, "tone_signals": ["Legal victory", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.039502, "evidence_share": 1.5, "evidence_share_display": "1.5", "freshness_pct": 19.1, "age_days": 16.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action \u2013 GRAL", "summary": "Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements and/or concealed material adverse facts regarding its NHS-Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the Rosen Law Firm to join the class action and potentially recover damages.", "url": "https://wahanariau.com/amp/48907/gral-deadline-alert-rosen-a-global-and-leading-law-firm-encourages-grail-inc-investors-to-secure-counsel-before-important-august-4-deadline-in-securities-class-action-%E2%80%93-gral", "source_link": "https://wahanariau.com/amp/48907/gral-deadline-alert-rosen-a-global-and-leading-law-firm-encourages-grail-inc-investors-to-secure-counsel-before-important-august-4-deadline-in-securities-class-action-%E2%80%93-gral", "source_link_is_lookup": false, "source_name": "wahanariau.com", "published_at": "2026-07-27T22:50:21", "published_display": "27 Jul 2026 22:50", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["wahanariau.com"], "source_kind": "publisher", "story_key": "90fb45d60929ecc64529a8a6278d8559c2b15b64310accc433f566491d2bbb18", "target_scope": "GRAL DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GRAIL, Inc. Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements and/or concealed material adverse facts regarding its NHS-Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.4778, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.055093, "evidence_share": 2.0, "evidence_share_display": "2", "freshness_pct": 18.4, "age_days": 17.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "$GRAL Lawsuit Notice: BFA Law Reminds GRAIL, Inc. Investors", "summary": "BFA Law has filed a securities fraud class action lawsuit against GRAIL, Inc. following a 50% stock drop. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial by making positive statements about the trial's design and results, despite the three-year timeframe being insufficient to demonstrate the primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case.", "url": "https://www.globenewswire.com/news-release/2026/07/27/3333411/0/en/gral-lawsuit-notice-bfa-law-reminds-grail-inc-investors-of-august-4-lead-plaintiff-deadline-after-50-stock-drop-triggers-securities-fraud-class-action.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/27/3333411/0/en/gral-lawsuit-notice-bfa-law-reminds-grail-inc-investors-of-august-4-lead-plaintiff-deadline-after-50-stock-drop-triggers-securities-fraud-class-action.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-27T11:40:22", "published_display": "27 Jul 2026 11:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "f1d72d47fec3e22d4104b30aee4816239d429be80852e948f4377b6d86292adb", "target_scope": "$GRAL Lawsuit Notice: BFA Law Reminds GRAIL, Inc. BFA Law has filed a securities fraud class action lawsuit against GRAIL, Inc. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial by making positive statements about the trial's design and results, despite the three-year timeframe being insufficient to demonstrate the primary endpoint.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.573, "provider_directional_mass": 0.8167, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.894, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Legal victory", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.031513, "evidence_share": 1.2, "evidence_share_display": "1.2", "freshness_pct": 17.6, "age_days": 17.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "AUGUST 4, 2026 GRAL DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit", "summary": "Robbins Geller Rudman & Dowd LLP announces a shareholder class action lawsuit against GRAIL, Inc. and its executives for alleged Securities Exchange Act violations. The lawsuit claims that Grail made false and misleading statements regarding its NHS-Galleri trial's primary endpoint, which was not achieved, leading to a significant stock price drop. Investors who suffered substantial losses between", "url": "https://www.newsfilecorp.com/release/306507/AUGUST-4-2026-GRAL-DEADLINE-GRAIL-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Shareholder-Class-Action-Lawsuit?lang=fr", "source_link": "https://www.newsfilecorp.com/release/306507/AUGUST-4-2026-GRAL-DEADLINE-GRAIL-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Shareholder-Class-Action-Lawsuit?lang=fr", "source_link_is_lookup": false, "source_name": "TMX Newsfile", "published_at": "2026-07-27T10:40:58", "published_display": "27 Jul 2026 10:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["TMX Newsfile"], "source_kind": "publisher", "story_key": "073c063f42255d886c3c97a3e481d68424528a716d208fe51e23c84fb4a02ebb", "target_scope": "AUGUST 4, 2026 GRAL DEADLINE: GRAIL, Inc. Robbins Geller Rudman & Dowd LLP announces a shareholder class action lawsuit against GRAIL, Inc. The lawsuit claims that Grail made false and misleading statements regarding its NHS-Galleri trial's primary endpoint, which was not achieved, leading to a significant stock price drop.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.8, "provider_directional_mass": 0.6078, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 13, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.082055, "evidence_share": 3.0, "evidence_share_display": "3", "freshness_pct": 17.5, "age_days": 17.6, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, Inc. ($GRAL) Investors Notified of August 4 Court Deadline in Securities Fraud Lawsuit Over Trial Results Allegations", "summary": "A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and its executives for securities fraud, stemming from a significant stock drop after the NHS-Galleri cancer trial failed to meet its primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case, which alleges the company made misleading statements about the trial's design and results. The lawsuit claims GRAIL's stock fell over 50% following the announcement that the trial did not show a statistically significant reduction in late-stage cancers.", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/grail-inc.-gral-investors-notified-of-august-4-court-deadline-in-1195458", "source_link": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/grail-inc.-gral-investors-notified-of-august-4-court-deadline-in-1195458", "source_link_is_lookup": false, "source_name": "ACCESS Newswire", "published_at": "2026-07-27T03:40:12", "published_display": "27 Jul 2026 03:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["ACCESS Newswire"], "source_kind": "publisher", "story_key": "2bc35efc98e60bb8ec7c7dd4fdd193a7969c09d2d74e5558c57146e820248ac8", "target_scope": "GRAIL, Inc. ($GRAL) Investors Notified of August 4 Court Deadline in Securities Fraud Lawsuit Over Trial Results Allegations A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and its executives for securities fraud, stemming from a significant stock drop after the NHS-Galleri cancer trial failed to meet its primary endpoint. The lawsuit claims GRAIL's stock fell over 50% following the announcement that the trial did not show a statistically significant reduction in late-stage cancers.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": 0.4739, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 12, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.084742, "evidence_share": 3.1, "evidence_share_display": "3.1", "freshness_pct": 17.0, "age_days": 17.9, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL Inc Revenue Breakdown \u2013 HAN:NL0", "summary": "GRAIL Inc (NL0) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top segment, Screening, showing an increase from the previous year's 104.93 million EUR. The United States was the largest contributor to the company's revenue, accounting for 116.72 million EUR.", "url": "https://www.tradingview.com/symbols/HAN-NL0/financials-segments", "source_link": "https://www.tradingview.com/symbols/HAN-NL0/financials-segments", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-24T22:41:40", "published_display": "24 Jul 2026 22:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["FDS", "GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "24e7ad896847bd83a2a2acf33cb98742f52b2134985f8b99e4b7dff82a4981b0", "target_scope": "GRAIL Inc Revenue Breakdown \u2013 HAN:NL0 GRAIL Inc (NL0) generated 125.31 million EUR in revenue last year.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.0355, "relevance_score": 0.72, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003713, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 6.2, "age_days": 20.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail", "summary": "Priority Health has partnered with Color Health and Grail to introduce two new cancer support solutions for self-funded employers. These solutions, available from January 1, 2027, will offer virtual cancer navigation, support, and multi-cancer early detection to Priority Health's 1.4 million members. The aim is to proactively address cancer earlier, provide personalized support, and potentially reduce healthcare costs associated with late-stage diagnoses.", "url": "https://medcitynews.com/2026/07/priority-health-launches-2-cancer-support-solutions-with-color-health-grail", "source_link": "https://medcitynews.com/2026/07/priority-health-launches-2-cancer-support-solutions-with-color-health-grail", "source_link_is_lookup": false, "source_name": "MedCity News", "published_at": "2026-07-24T17:41:40", "published_display": "24 Jul 2026 17:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["MedCity News"], "source_kind": "publisher", "story_key": "5d9f02ad2fb11f259a83bba685774333c7cd434e135fd77f73a7b7bcd7fa7196", "target_scope": "Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail Priority Health has partnered with Color Health and Grail to introduce two new cancer support solutions for self-funded employers.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": 0.4076, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 7.6e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 20.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Shareholder Alert: GRAIL, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm", "summary": "The Gross Law Firm has issued a shareholder alert for investors of GRAIL, Inc. (GRAL), announcing a securities class action lawsuit. Investors who purchased GRAL shares between May 13, 2020, and February 19, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment. The lawsuit alleges that GRAIL defendants made misleading statements and concealed adverse facts about the company's NHS-Galleri trial results, leading to a significant stock price drop.", "url": "https://www.lincolnjournal.com/online_features/press_releases/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit---investors-should-contact-the/article_94708ee2-d16a-587d-a4c1-0d423f4e6816.html", "source_link": "https://www.lincolnjournal.com/online_features/press_releases/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit---investors-should-contact-the/article_94708ee2-d16a-587d-a4c1-0d423f4e6816.html", "source_link_is_lookup": false, "source_name": "lincolnjournal.com", "published_at": "2026-07-24T17:12:52", "published_display": "24 Jul 2026 17:12", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["lincolnjournal.com"], "source_kind": "publisher", "story_key": "796c603eb8c39308e6fb51d3b4400c4528d51c6c7fea210f427a27632091849e", "target_scope": "GRAL Shareholder Alert: GRAIL, Inc. The Gross Law Firm has issued a shareholder alert for investors of GRAIL, Inc. (GRAL), announcing a securities class action lawsuit. Investors who purchased GRAL shares between May 13, 2020, and February 19, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment. The lawsuit alleges that GRAIL defendants made misleading statements and concealed adverse facts about the company's NHS-Galleri trial results, leading to a significant stock price drop.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.765, "provider_directional_mass": 0.9395, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 16, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.056683, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 13.4, "age_days": 20.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline", "summary": "Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) following a significant stock price drop. The lawsuit alleges that GRAIL and its executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, specifically regarding a three-year follow-up period that proved insufficient. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and incurred substantial losses, have until August 4, 2026, to seek lead plaintiff status.", "url": "https://www.prnewswire.com/news-releases/hagens-berman-sobol-shapiro-llp-alert-grail-inc-nasdaq-gral-investors-urged-to-contact-hagens-berman-securities-fraud-class-action-filed-august-4-2026-lead-plaintiff-deadline-302833795.html", "source_link": "https://www.prnewswire.com/news-releases/hagens-berman-sobol-shapiro-llp-alert-grail-inc-nasdaq-gral-investors-urged-to-contact-hagens-berman-securities-fraud-class-action-filed-august-4-2026-lead-plaintiff-deadline-302833795.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-24T12:12:52", "published_display": "24 Jul 2026 12:12", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL", "GRAL.ARCHIVE"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["PR Newswire"], "source_kind": "press_release", "story_key": "a7bc0eae168878f41bc7e13ddbd69dd5e39766c21f9ca2698184f38fc02df007", "target_scope": "HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) following a significant stock price drop. The lawsuit alleges that GRAIL and its executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, specifically regarding a three-year follow-up period that proved insufficient. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and incurred substantial losses, have until August 4, 2026, to seek lead plaintiff status.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.628, "provider_directional_mass": 0.9392, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.618, "sentiment": "negative", "sentiment_pct": 44, "tone_signals": ["Legal victory", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030696, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 13.1, "age_days": 20.5, "influence_label": "Low", "duplicate_count": 3, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results \u2013 Investors Notified to Contact BFA Law", "summary": "A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) due to a 50% stock dive following allegations that the company misrepresented results from its NHS-Galleri cancer trial. The lawsuit claims GRAIL misled investors regarding the trial's effectiveness and its ability to achieve its primary endpoint of reducing late-stage cancers within the stated three-year timeframe. Investors are encouraged to contact BFA Law to discuss their legal options, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/24/3332754/0/en/GRAL-Fraud-Notification-GRAIL-Inc-Sued-for-Fraud-Over-Misrepresentations-about-its-Trial-Results-Investors-Notified-to-Contact-BFA-Law.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/24/3332754/0/en/GRAL-Fraud-Notification-GRAIL-Inc-Sued-for-Fraud-Over-Misrepresentations-about-its-Trial-Results-Investors-Notified-to-Contact-BFA-Law.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-24T10:12:52", "published_display": "24 Jul 2026 10:12", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "4359245827d4036aaab3a3070f287f8cc08cc5bba2dff29960561599809be3bc", "target_scope": "$GRAL Fraud Notification: GRAIL, Inc. A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) due to a 50% stock dive following allegations that the company misrepresented results from its NHS-Galleri cancer trial. The lawsuit claims GRAIL misled investors regarding the trial's effectiveness and its ability to achieve its primary endpoint of reducing late-stage cancers within the stated three-year timeframe.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.4941, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.044037, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 13.0, "age_days": 20.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "How Grail Inc Com (GRAL) Affects Rotational Strategy Timing", "summary": "The article analyzes Grail Inc Com (GRAL) through a quantitative research lens, highlighting weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies resistance levels and an exceptional short setup with significant downside potential against low risk. Several institutional trading strategies, including position, momentum, and risk hedging, are detailed along with multi-timeframe signal analysis to guide investors.", "url": "https://news.stocktradersdaily.com/news_release/89/How_Grail_Inc_Com_GRAL_Affects_Rotational_Strategy_Timing_072426030603_1784876763.html", "source_link": "https://news.stocktradersdaily.com/news_release/89/How_Grail_Inc_Com_GRAL_Affects_Rotational_Strategy_Timing_072426030603_1784876763.html", "source_link_is_lookup": false, "source_name": "Stock Traders Daily", "published_at": "2026-07-24T03:10:37", "published_display": "24 Jul 2026 03:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Stock Traders Daily"], "source_kind": "publisher", "story_key": "f7a89c3337be8c53b20aa96af402fa69c4fb1d09eab968af6b5a2e336bdcf118", "target_scope": "How Grail Inc Com (GRAL) Affects Rotational Strategy Timing The article analyzes Grail Inc Com (GRAL) through a quantitative research lens, highlighting weak near-term sentiment that could precede shifts in its mid and long-term outlook.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.493, "provider_directional_mass": 0.011, "relevance_score": 0.72, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 37, "tone_signals": ["Negative financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.020447, "evidence_share": 0.8, "evidence_share_display": "0.8", "freshness_pct": 12.6, "age_days": 20.9, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026", "summary": "Faruqi & Faruqi, LLP reminds investors of a securities class action lawsuit against Grail, Inc. (GRAL) with a lead plaintiff deadline of August 4, 2026. The lawsuit alleges that Grail made misleading statements regarding the success of its NHS-Galleri cancer detection trial, which resulted in a significant stock price drop. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the law firm.", "url": "https://natlawreview.com/press-releases/gral-investor-deadline-approaching-faruqi-faruqi-llp-reminds-grail-gral", "source_link": "https://natlawreview.com/press-releases/gral-investor-deadline-approaching-faruqi-faruqi-llp-reminds-grail-gral", "source_link_is_lookup": false, "source_name": "The National Law Review", "published_at": "2026-07-24T01:10:37", "published_display": "24 Jul 2026 01:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["The National Law Review"], "source_kind": "publisher", "story_key": "73d36f121150b850bfd7876d4e26e150974553001c8660c38f0a32646488d441", "target_scope": "GRAL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026 Faruqi & Faruqi, LLP reminds investors of a securities class action lawsuit against Grail, Inc. (GRAL) with a lead plaintiff deadline of August 4, 2026. The lawsuit alleges that Grail made misleading statements regarding the success of its NHS-Galleri cancer detection trial, which resulted in a significant stock price drop.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.786, "provider_directional_mass": 0.7487, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.056261, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 12.5, "age_days": 21.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm", "summary": "Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, thereby harming investors who purchased securities between May 13, 2025, and February 19, 2026. Investors are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/23/3332410/9788/en/bronstein-gewirtz-grossman-llc-urges-grail-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/23/3332410/9788/en/bronstein-gewirtz-grossman-llc-urges-grail-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-23T16:09:10", "published_display": "23 Jul 2026 16:09", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "e6fd327a33987eaeca3312f5bfbabe0def7bc7f024287032a9b7baea7f1e648a", "target_scope": "Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, thereby harming investors who purchased securities between May 13, 2025, and February 19, 2026.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.65, "provider_directional_mass": 0.4314, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 21, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.04584, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 12.1, "age_days": 21.4, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact SueWallSt", "summary": "SueWallSt is announcing a securities class action lawsuit against Grail, Inc. (GRAL) on behalf of shareholders who experienced significant losses after the company's NHS-Galleri trial failed to meet its primary endpoint. Investors are encouraged to seek lead plaintiff status by August 4, 2026, though class members can still participate in a settlement even if they miss this deadline. The lawsuit alleges that Grail made misleading statements about the trial's progress and expected outcomes, leading to a 50.55% stock drop when the failure was disclosed.", "url": "https://www.tradingview.com/news/prnewswire:460c025b04926:0-lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery-contact-suewallst", "source_link": "https://www.tradingview.com/news/prnewswire:460c025b04926:0-lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery-contact-suewallst", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-23T14:10:37", "published_display": "23 Jul 2026 14:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "cfe7fe7a0974226936045b720dec296a83f240e859491eecd5e9b288b351f66f", "target_scope": "Lost Money on Grail, Inc. (GRAL)? SueWallSt is announcing a securities class action lawsuit against Grail, Inc. (GRAL) on behalf of shareholders who experienced significant losses after the company's NHS-Galleri trial failed to meet its primary endpoint. The lawsuit alleges that Grail made misleading statements about the trial's progress and expected outcomes, leading to a 50.55% stock drop when the failure was disclosed.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": 0.8123, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.087, "sentiment": "negative", "sentiment_pct": 13, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.058531, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 12.0, "age_days": 21.5, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against GRAIL, Inc. (GRAL)", "summary": "Bernstein Liebhard LLP has announced a securities class action lawsuit filed against GRAIL, Inc. on behalf of investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements, leading to artificially inflated stock prices and significant losses for investors. Shareholders are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/23/3332262/0/en/shareholder-alert-bernstein-liebhard-llp-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-grail-inc-gral.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/23/3332262/0/en/shareholder-alert-bernstein-liebhard-llp-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-grail-inc-gral.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-23T13:10:37", "published_display": "23 Jul 2026 13:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "56af824fdd3597adee260fca47a617b0857129b7e3ee76fba658e314f04ea32f", "target_scope": "SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against GRAIL, Inc. (GRAL) Bernstein Liebhard LLP has announced a securities class action lawsuit filed against GRAIL, Inc. The lawsuit alleges that GRAIL made false and misleading statements, leading to artificially inflated stock prices and significant losses for investors.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.688, "provider_directional_mass": 0.7486, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 15, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.052286, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 11.9, "age_days": 21.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026", "summary": "Bernstein Liebhard LLP reminds investors of GRAIL, Inc. (NASDAQ: GRAL) that they have until August 4, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, causing investors to suffer losses. Investors who purchased shares during this period and wish to serve as lead plaintiff must file papers by the deadline.", "url": "https://www.globenewswire.com/news-release/2026/07/22/3331458/0/en/GRAIL-INC-INVESTORS-WITH-LOSSES-HAVE-UNTIL-AUGUST-4-2026-TO-JOIN-SECURITIES-CLASS-ACTION-Bernstein-Liebhard-LLP-Announces-Deadline.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/22/3331458/0/en/GRAIL-INC-INVESTORS-WITH-LOSSES-HAVE-UNTIL-AUGUST-4-2026-TO-JOIN-SECURITIES-CLASS-ACTION-Bernstein-Liebhard-LLP-Announces-Deadline.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-22T13:42:10", "published_display": "22 Jul 2026 13:42", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "8481273aa52e093e7447f60876fa6006ecafd4c1c30a74700305b09b50c270ea", "target_scope": "GRAIL, INC. Bernstein Liebhard LLP reminds investors of GRAIL, Inc. (NASDAQ: GRAL) that they have until August 4, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, causing investors to suffer losses.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.671, "provider_directional_mass": 0.7313, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 18, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.044599, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 10.8, "age_days": 22.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Deadline Alert: Levi & Korsinsky Reminds Grail, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026", "summary": "Levi & Korsinsky reminds investors of Grail, Inc. (NASDAQ: GRAL) that the deadline to apply for lead plaintiff in a securities class action lawsuit is August 4, 2026. This lawsuit follows a significant stock drop after Grail's NHS-Galleri trial failed its primary endpoint, resulting in losses of over 50% for investors who purchased securities between May 13, 2025, and February 19, 2026. The firm encourages affected shareholders to contact them to evaluate their eligibility to recover losses or serve as a lead plaintiff.", "url": "https://www.morningstar.com/news/pr-newswire/20260722ny09414/gral-deadline-alert-levi-korsinsky-reminds-grail-inc-gral-investors-of-securities-class-action-deadline-on-august-4-2026", "source_link": "https://www.morningstar.com/news/pr-newswire/20260722ny09414/gral-deadline-alert-levi-korsinsky-reminds-grail-inc-gral-investors-of-securities-class-action-deadline-on-august-4-2026", "source_link_is_lookup": false, "source_name": "Morningstar", "published_at": "2026-07-22T13:42:10", "published_display": "22 Jul 2026 13:42", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL", "GRAL.ARCHIVE"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Morningstar"], "source_kind": "publisher", "story_key": "bd4bcaacc669bb98ccc10004e7e1ab228b74731eb14a87e60ae90fafe1ee4f04", "target_scope": "GRAL Deadline Alert: Levi & Korsinsky Reminds Grail, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026 Levi & Korsinsky reminds investors of Grail, Inc. (NASDAQ: GRAL) that the deadline to apply for lead plaintiff in a securities class action lawsuit is August 4, 2026. This lawsuit follows a significant stock drop after Grail's NHS-Galleri trial failed its primary endpoint, resulting in losses of over 50% for investors who purchased securities between May 13, 2025, and February 19, 2026.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.786, "provider_directional_mass": 0.6293, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.066421, "evidence_share": 2.5, "evidence_share_display": "2.5", "freshness_pct": 10.8, "age_days": 22.5, "influence_label": "Low", "duplicate_count": 5, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman", "summary": "Hagens Berman is investigating GRAIL, Inc. (NASDAQ: GRAL) for alleged securities law violations in connection with its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL misled investors about the trial's design and efficacy, particularly regarding the adequacy of the three-year follow-up period, leading to a significant stock drop after the trial failed its primary endpoint. Investors who suffered substantial losses are encouraged to come forward and have until August 4, 2026, to seek lead plaintiff status.", "url": "https://www.prnewswire.com/news-releases/investor-notice-grail-inc-gral-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-hagens-berman-302831217.html", "source_link": "https://www.prnewswire.com/news-releases/investor-notice-grail-inc-gral-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-hagens-berman-302831217.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-21T20:11:49", "published_display": "21 Jul 2026 20:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["PR Newswire"], "source_kind": "press_release", "story_key": "9c71ea6c8f28ecad4c80e4bc58614410325ee1f7f9fc646ef7edb880caa02c5f", "target_scope": "INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman Hagens Berman is investigating GRAIL, Inc. (NASDAQ: GRAL) for alleged securities law violations in connection with its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL misled investors about the trial's design and efficacy, particularly regarding the adequacy of the three-year follow-up period, leading to a significant stock drop after the trial failed its primary endpoint.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.765, "provider_directional_mass": 0.8473, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 16, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.048322, "evidence_share": 1.8, "evidence_share_display": "1.8", "freshness_pct": 10.1, "age_days": 23.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors", "summary": "The Portnoy Law Firm has announced a class action lawsuit on behalf of investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated false and misleading statements about the NHS-Galleri trial, concealing that the trial period was insufficient to achieve its primary endpoint of reducing Stage III-IV cancers. Investors have until August 4, 2026, to file a lead plaintiff motion.", "url": "https://www.wboc.com/online_features/press_releases/portnoy-law-firm-announces-class-action-on-behalf-of-grail-inc-investors/article_3ea64be0-b68b-5693-9f52-aeaa7c8a1868.html", "source_link": "https://www.wboc.com/online_features/press_releases/portnoy-law-firm-announces-class-action-on-behalf-of-grail-inc-investors/article_3ea64be0-b68b-5693-9f52-aeaa7c8a1868.html", "source_link_is_lookup": false, "source_name": "WBOC TV", "published_at": "2026-07-21T14:10:19", "published_display": "21 Jul 2026 14:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["WBOC TV"], "source_kind": "publisher", "story_key": "2df7c67c144d784791daa235117b2edb21b23c1ef432c5921416070a9100df6d", "target_scope": "Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. The Portnoy Law Firm has announced a class action lawsuit on behalf of investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated false and misleading statements about the NHS-Galleri trial, concealing that the trial period was insufficient to achieve its primary endpoint of reducing Stage III-IV cancers.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.0003, "relevance_score": 0.72, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024004, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 9.8, "age_days": 23.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Enterprise value to EBIT forward of GRAIL, Inc. \u2013 NASDAQ:GRAL", "summary": "This article from TradingView provides a financial metric for GRAIL, Inc. (NASDAQ: GRAL), specifically its enterprise value to EBIT (Earnings Before Interest and Taxes) forward. The content is primarily a title and navigational elements, indicating the company's listing on the Nasdaq Stock Market under the Health Technology sector. The presented information is limited to the company name and the financial metric.", "url": "https://www.tradingview.com/symbols/NASDAQ-GRAL/financials-statistics-and-ratios/enterprise-value-ebit-fwd", "source_link": "https://www.tradingview.com/symbols/NASDAQ-GRAL/financials-statistics-and-ratios/enterprise-value-ebit-fwd", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-21T11:10:19", "published_display": "21 Jul 2026 11:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "d8a1b5ef0154380c192061ca594cc758be409016cee9c4cb38e684e0cee838d9", "target_scope": "Enterprise value to EBIT forward of GRAIL, Inc. \u2013 NASDAQ:GRAL This article from TradingView provides a financial metric for GRAIL, Inc. (NASDAQ: GRAL), specifically its enterprise value to EBIT (Earnings Before Interest and Taxes) forward.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.0339, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003655, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 3.8, "age_days": 23.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences", "Earnings"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Lawsuit Notice: $GRAL Legal News: GRAIL, Inc. Trial Results and 50% Stock Drop Trigger Securities Fraud Class Action", "summary": "Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who purchased GRAIL stock are encouraged to contact the law firm to learn about their legal options, with a lead plaintiff deadline of August 4, 2026.", "url": "https://www.prnewswire.com/news-releases/lawsuit-notice-gral-legal-news-grail-inc-trial-results-and-50-stock-drop-trigger-securities-fraud-class-action-302830328.html", "source_link": "https://www.prnewswire.com/news-releases/lawsuit-notice-gral-legal-news-grail-inc-trial-results-and-50-stock-drop-trigger-securities-fraud-class-action-302830328.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-21T10:10:19", "published_display": "21 Jul 2026 10:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["PR Newswire"], "source_kind": "press_release", "story_key": "16518267bc02c96a54d0f154283cb8ab1ceec7c86eccb6b920cae82b8d921b0f", "target_scope": "Lawsuit Notice: $GRAL Legal News: GRAIL, Inc. Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who purchased GRAIL stock are encouraged to contact the law firm to learn about their legal options, with a lead plaintiff deadline of August 4, 2026.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": 0.7319, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 12, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.054461, "evidence_share": 2.0, "evidence_share_display": "2", "freshness_pct": 9.6, "age_days": 23.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit", "summary": "Glancy Prongay Wolke & Rotter LLP reminds investors of Grail, Inc. (GRAL) about an upcoming August 4, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that Grail made misleading statements during the Class Period of May 13, 2025, to February 19, 2026, regarding its NHS-Galleri Trial, after which the stock price dropped significantly. Investors who suffered losses are encouraged to contact the firm to inquire about pursuing claims.", "url": "https://www.globenewswire.com/news-release/2026/07/20/3330049/0/en/deadline-alert-grail-inc-gral-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3330049/0/en/deadline-alert-grail-inc-gral-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-21T08:11:49", "published_display": "21 Jul 2026 08:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "5d6d42256370d27831b0e6522fc7cf4e9b261ec585593dca753fce4c8d434fa0", "target_scope": "Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit Glancy Prongay Wolke & Rotter LLP reminds investors of Grail, Inc. (GRAL) about an upcoming August 4, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that Grail made misleading statements during the Class Period of May 13, 2025, to February 19, 2026, regarding its NHS-Galleri Trial, after which the stock price dropped significantly.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.765, "provider_directional_mass": 0.6411, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 16, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.045988, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 9.6, "age_days": 23.7, "influence_label": "Low", "duplicate_count": 3, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Role", "summary": "Bragar Eagel & Squire, P.C. has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false or misleading statements regarding its NHS Galleri trial, specifically concerning the insufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors have until August 4, 2026, to apply to be appointed as lead plaintiff.", "url": "https://www.globenewswire.com/news-release/2026/07/20/3330153/0/en/bragar-eagel-squire-p-c-reminds-grail-inc-investors-they-have-until-august-4th-to-contact-the-firm-seeking-lead-plaintiff-role.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3330153/0/en/bragar-eagel-squire-p-c-reminds-grail-inc-investors-they-have-until-august-4th-to-contact-the-firm-seeking-lead-plaintiff-role.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-20T22:09:42", "published_display": "20 Jul 2026 22:09", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "e1fc9ce7ca83d171c962cffaa70a936cc70c984d6ea861f97e0b82403d2e6832", "target_scope": "Reminds GRAIL, Inc. has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false or misleading statements regarding its NHS Galleri trial, specifically concerning the insufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.4388, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.031132, "evidence_share": 1.2, "evidence_share_display": "1.2", "freshness_pct": 9.2, "age_days": 24.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP has issued a shareholder alert for Grail, Inc. (NASDAQ: GRAL) investors, announcing a securities class action lawsuit. The lawsuit alleges that Grail misled investors regarding its NHS-Galleri trial, which was projected to achieve a statistically significant reduction in late-stage cancers but failed to meet its primary endpoint, causing a 50.55% stock drop. Investors who purchased shares during the Class Period (May 13, 2025, through February 19, 2026) are encouraged to contact the law firm to learn about recovering their losses.", "url": "https://www.globenewswire.com/news-release/2026/07/20/3329863/3080/en/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit-investors-should-contact-levi-korsinsky.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3329863/3080/en/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit-investors-should-contact-levi-korsinsky.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-20T14:40:55", "published_display": "20 Jul 2026 14:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "c0a19daff1d6a0f40f7e60957f75e82fe1fbacd1d635b3317b54e8118b28f9be", "target_scope": "GRAL Shareholder Alert: Grail, Inc. Levi & Korsinsky, LLP has issued a shareholder alert for Grail, Inc. (NASDAQ: GRAL) investors, announcing a securities class action lawsuit. The lawsuit alleges that Grail misled investors regarding its NHS-Galleri trial, which was projected to achieve a statistically significant reduction in late-stage cancers but failed to meet its primary endpoint, causing a 50.55% stock drop.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": 0.6087, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 9, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.051901, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 8.9, "age_days": 24.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS", "summary": "Hagens Berman is investigating a securities class action against GRAIL, Inc. (GRAL) following a $2.2 billion market cap wipeout after its NHS-Galleri cancer screening trial failed to meet its primary endpoint. The lawsuit alleges that GRAIL misled investors by concealing insufficient trial design and withholding critical data regarding the efficacy and timeline of the study. Investors who suffered losses between May 13, 2025, and Feb. 19, 2026, are encouraged to come forward by the lead plaintiff deadline of August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/20/3329814/0/en/GRAIL-Inc-GRAL-Faces-Securities-Class-Action-Amid-NHS-Galleri-Trial-Failure-2-2B-Market-Cap-Wipeout-HBSS.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3329814/0/en/GRAIL-Inc-GRAL-Faces-Securities-Class-Action-Amid-NHS-Galleri-Trial-Failure-2-2B-Market-Cap-Wipeout-HBSS.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-20T09:44:00", "published_display": "20 Jul 2026 09:44", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "60a31af44358546558226a8a091474cfc7bede9a808830f31868d399b6808d0a", "target_scope": "GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS Hagens Berman is investigating a securities class action against GRAIL, Inc. (GRAL) following a $2.2 billion market cap wipeout after its NHS-Galleri cancer screening trial failed to meet its primary endpoint. The lawsuit alleges that GRAIL misled investors by concealing insufficient trial design and withholding critical data regarding the efficacy and timeline of the study.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.769, "provider_directional_mass": 0.8028, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 14, "tone_signals": ["Failed To Meet", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.043672, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 8.7, "age_days": 24.6, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GRAIL, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and certain officers. The lawsuit claims that defendants made misleading statements between May 13, 2025, and February 19, 2026, regarding the likelihood of success in Grail's NHS-Galleri trial. Investors who suffered losses are encouraged to join the case and have until August 4, 2026, to request to be appointed as lead plaintiff.", "url": "https://natlawreview.com/press-releases/gral-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-grail-1", "source_link": "https://natlawreview.com/press-releases/gral-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-grail-1", "source_link_is_lookup": false, "source_name": "The National Law Review", "published_at": "2026-07-19T05:09:56", "published_display": "19 Jul 2026 05:09", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["The National Law Review"], "source_kind": "publisher", "story_key": "ad32b9ad30256fc7c94c3dee77d5683283d3277aab115fdb38b35d1c74fd6256", "target_scope": "GRAL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GRAIL, Inc. Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and certain officers. The lawsuit claims that defendants made misleading statements between May 13, 2025, and February 19, 2026, regarding the likelihood of success in Grail's NHS-Galleri trial.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.688, "provider_directional_mass": 0.638, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 15, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030037, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 7.8, "age_days": 25.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, Inc. Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit", "summary": "The Rosen Law Firm reminds purchasers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, that they have an opportunity to lead a securities fraud class action lawsuit. Investors who bought GRAIL common stock during this period can seek compensation without upfront fees, and the deadline to move the Court to serve as lead plaintiff is August 4, 2026. The lawsuit alleges that GRAIL provided misleading positive statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial results, causing damages to investors.", "url": "https://www.keybiscayneportal.com/online_features/press_releases/grail-inc-deadline-gral-investors-have-opportunity-to-lead-grail-inc-securities-fraud-lawsuit/article_45b5e25f-fd6d-5c0c-b976-ab2e92d1e6cf.html", "source_link": "https://www.keybiscayneportal.com/online_features/press_releases/grail-inc-deadline-gral-investors-have-opportunity-to-lead-grail-inc-securities-fraud-lawsuit/article_45b5e25f-fd6d-5c0c-b976-ab2e92d1e6cf.html", "source_link_is_lookup": false, "source_name": "Key Biscayne Portal", "published_at": "2026-07-18T19:40:55", "published_display": "18 Jul 2026 19:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Key Biscayne Portal"], "source_kind": "publisher", "story_key": "ad5e89648b6965f74b158d351ba1ab166f8af78b73d95aefb19399e074f8a6c4", "target_scope": "GRAIL, Inc. Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. The Rosen Law Firm reminds purchasers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, that they have an opportunity to lead a securities fraud class action lawsuit. Investors who bought GRAIL common stock during this period can seek compensation without upfront fees, and the deadline to move the Court to serve as lead plaintiff is August 4, 2026. The lawsuit alleges that GRAIL provided misleading positive statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial results, causing damages to investors.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.603, "provider_directional_mass": 0.6482, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.236, "sentiment": "negative", "sentiment_pct": 33, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.018777, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 7.5, "age_days": 26.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, INC. DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL,", "summary": "The Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial's sufficiency in demonstrating cancer reduction. Investors are encouraged to secure counsel to pursue potential compensation.", "url": "https://www.globenewswire.com/news-release/2026/07/17/3329331/673/en/GRAIL-INC-DEADLINE-ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-GRAIL-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-GRAL.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/17/3329331/673/en/GRAIL-INC-DEADLINE-ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-GRAIL-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-GRAL.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-17T23:40:22", "published_display": "17 Jul 2026 23:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "3459dea583314cafbccc98c20f9b8b042b907cdb67b588ba5bb48992e950f82c", "target_scope": "GRAIL, INC. The Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial's sufficiency in demonstrating cancer reduction.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.4252, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023276, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 6.9, "age_days": 27.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL INVESTOR DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit", "summary": "Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against GRAIL, Inc. for alleged violations of the Securities Exchange Act of 1934. Investors who purchased GRAL common stock between May 13, 2025, and February 19, 2026, and suffered substantial losses, have until August 4, 2026, to seek appointment as lead plaintiff. The lawsuit claims Grail made misleading statements regarding its NHS-Galleri trial's primary endpoint, which ultimately failed to show a statistically significant reduction in late-stage cancers.", "url": "https://www.newsfilecorp.com/release/304848/GRAL-INVESTOR-DEADLINE-GRAIL-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit?lang=fr", "source_link": "https://www.newsfilecorp.com/release/304848/GRAL-INVESTOR-DEADLINE-GRAIL-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit?lang=fr", "source_link_is_lookup": false, "source_name": "TMX Newsfile", "published_at": "2026-07-17T19:50:00", "published_display": "17 Jul 2026 19:50", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["TMX Newsfile"], "source_kind": "publisher", "story_key": "64710e16b2f5070fc1e8fbc0880176d473500e44eea9356f234423b787b6b88c", "target_scope": "GRAL INVESTOR DEADLINE: GRAIL, Inc. Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against GRAIL, Inc. The lawsuit claims Grail made misleading statements regarding its NHS-Galleri trial's primary endpoint, which ultimately failed to show a statistically significant reduction in late-stage cancers.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.688, "provider_directional_mass": 0.6466, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 15, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.026178, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 6.8, "age_days": 27.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Director at GRAIL, Inc. (GRAL) receives 427 deferred stock units in fee swap", "summary": "GRAIL, Inc. Director Gregory L. Summe was granted 427 deferred stock units (DSUs) as compensation, valued at $31,787.67, in lieu of cash director fees. The DSUs, priced at $74.36 per unit, vested immediately on July 15, 2026, and increased his direct holdings to 45,672 shares. This transaction was reported in a Form 4 filing and summarized by Rhea-AI.", "url": "https://www.stocktitan.net/sec-filings/GRAL/form-4-grail-inc-insider-trading-activity-578c62f55bba.html", "source_link": "https://www.stocktitan.net/sec-filings/GRAL/form-4-grail-inc-insider-trading-activity-578c62f55bba.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-16T21:11:26", "published_display": "16 Jul 2026 21:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "b257f1bdd75ac782eee710f8f6ae06b27d36dc64f00c532994000a5d6bcbbb55", "target_scope": "Director at GRAIL, Inc. (GRAL) receives 427 deferred stock units in fee swap GRAIL, Inc.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.0106, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001936, "evidence_share": 0.1, "evidence_share_display": "<0.1", "freshness_pct": 2.0, "age_days": 28.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, Inc. (GRAL) director receives 276 deferred stock units as fees", "summary": "GRAIL, Inc. director William J. Chase was granted 276 deferred stock units on July 15, 2026, as compensation for director fees, totaling $20,568.49. These units, priced at $74.36 per share, vested immediately, increasing his direct holdings to 42,978 shares. This transaction was reported in a Form 4 filing and represents a conversion of cash fees into equity under the company's 2024 Equity Incentive Plan.", "url": "https://www.stocktitan.net/sec-filings/GRAL/form-4-grail-inc-insider-trading-activity-555e0a9c627c.html", "source_link": "https://www.stocktitan.net/sec-filings/GRAL/form-4-grail-inc-insider-trading-activity-555e0a9c627c.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-07-16T21:11:26", "published_display": "16 Jul 2026 21:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "73fda0d96df9a115f9497256ced5e1fd46428831d4c717b0a4ac8b28f905f178", "target_scope": "GRAIL, Inc. (GRAL) director receives 276 deferred stock units as fees GRAIL, Inc.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.0446, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 28.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Investor Alert: HBSS Probes GRAIL, Inc. (GRAL) Following Securities Class Action Over Failed NHS-Galleri Trial", "summary": "Hagens Berman is investigating GRAIL, Inc. (GRAL) following a class action lawsuit alleging the company misled investors about the design and efficacy of its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL concealed inadequate trial design and withheld critical data, leading to a significant stock price collapse after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to submit their claims by August 4, 2026.", "url": "https://www.globenewswire.com/news-release/2026/07/15/3328178/32716/en/gral-investor-alert-hbss-probes-grail-inc-gral-following-securities-class-action-over-failed-nhs-galleri-trial.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/15/3328178/32716/en/gral-investor-alert-hbss-probes-grail-inc-gral-following-securities-class-action-over-failed-nhs-galleri-trial.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-16T18:11:16", "published_display": "16 Jul 2026 18:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "f2b0df82fc79ba6cce0000e7e4768bce9f8376e31d2810efdcefcc5f7160dbfb", "target_scope": "GRAL Investor Alert: HBSS Probes GRAIL, Inc. (GRAL) Following Securities Class Action Over Failed NHS-Galleri Trial Hagens Berman is investigating GRAIL, Inc. (GRAL) following a class action lawsuit alleging the company misled investors about the design and efficacy of its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL concealed inadequate trial design and withheld critical data, leading to a significant stock price collapse after the trial failed to meet its primary endpoint.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.795, "provider_directional_mass": 0.9152, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 12, "tone_signals": ["Failed To Meet", "Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.032168, "evidence_share": 1.2, "evidence_share_display": "1.2", "freshness_pct": 6.1, "age_days": 28.3, "influence_label": "Low", "duplicate_count": 2, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs GRAIL, Inc. (GRAL) Investors of a Securities Fraud Lawsuit", "summary": "Berger Montague PC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL concealed material inadequacies in the NHS-Galleri trial design, leading to the trial's failure to achieve its primary endpoint. Following this announcement, GRAIL's stock plummeted by over 50%.", "url": "https://www.marketscreener.com/news/grail-inc-securities-fraud-notice-berger-montague-informs-grail-inc-gral-investors-of-a-secur-ce7f5ed3db8bf124", "source_link": "https://www.marketscreener.com/news/grail-inc-securities-fraud-notice-berger-montague-informs-grail-inc-gral-investors-of-a-secur-ce7f5ed3db8bf124", "source_link_is_lookup": false, "source_name": "www.marketscreener.com", "published_at": "2026-07-16T14:10:14", "published_display": "16 Jul 2026 14:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL", "GRAL.ARCHIVE"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["www.marketscreener.com"], "source_kind": "publisher", "story_key": "0b857f895e2e24c93f0a01ee9bc03cf92141837c69b1c70fd3cada75c77952f9", "target_scope": "GRAIL, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs GRAIL, Inc. (GRAL) Investors of a Securities Fraud Lawsuit Berger Montague PC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL concealed material inadequacies in the NHS-Galleri trial design, leading to the trial's failure to achieve its primary endpoint.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.619, "provider_directional_mass": 0.5251, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.017886, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 6.0, "age_days": 28.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL DEADLINE: SueWallSt Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline", "summary": "SueWallSt is reminding investors of Grail, Inc. (NASDAQ: GRAL) about an upcoming securities class action deadline of August 4, 2026. The lawsuit alleges that Grail's leadership withheld detailed results from the NHS-Galleri trial, leading to a 50.55% stock plunge after the trial failed to meet its primary endpoint. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and suffered losses, may be eligible to join the lawsuit.", "url": "https://www.prnewswire.com/news-releases/gral-deadline-suewallst-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline-302827273.html", "source_link": "https://www.prnewswire.com/news-releases/gral-deadline-suewallst-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline-302827273.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-16T14:10:14", "published_display": "16 Jul 2026 14:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["PR Newswire"], "source_kind": "press_release", "story_key": "60f0e7d28ec71103068ad6e0f1a99130f0376f25c8f645ed1043a530655e8f95", "target_scope": "GRAL DEADLINE: SueWallSt Reminds Grail, Inc. SueWallSt is reminding investors of Grail, Inc. (NASDAQ: GRAL) about an upcoming securities class action deadline of August 4, 2026. The lawsuit alleges that Grail's leadership withheld detailed results from the NHS-Galleri trial, leading to a 50.55% stock plunge after the trial failed to meet its primary endpoint. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and suffered losses, may be eligible to join the lawsuit.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": 0.7249, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 11, "tone_signals": ["Failed To Meet", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.034217, "evidence_share": 1.3, "evidence_share_display": "1.3", "freshness_pct": 6.0, "age_days": 28.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri\u00ae Multi-Cancer Early Detection Blood Test to Employer Plans", "summary": "Priority Health, a leading Michigan health plan, has partnered with GRAIL to offer the Galleri multi-cancer early detection blood test to its self-insured employer groups, making it the first in Michigan to do so. This expansion follows Priority Health's earlier integration of Galleri into its Medicare Advantage plans, aiming to improve early cancer detection, reduce healthcare costs, and enhance patient outcomes by identifying cancers before symptoms appear. The Galleri test screens for over 50 cancer types with a simple blood draw, complementing existing standard-of-care screenings.", "url": "https://www.prnewswire.com/news-releases/priority-health-collaborates-with-grail-as-the-first-michigan-health-plan-to-offer-the-galleri-multi-cancer-early-detection-blood-test-to-employer-plans-302827214.html", "source_link": "https://www.prnewswire.com/news-releases/priority-health-collaborates-with-grail-as-the-first-michigan-health-plan-to-offer-the-galleri-multi-cancer-early-detection-blood-test-to-employer-plans-302827214.html", "source_link_is_lookup": false, "source_name": "PR Newswire", "published_at": "2026-07-16T13:10:14", "published_display": "16 Jul 2026 13:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["PR Newswire"], "source_kind": "press_release", "story_key": "15b0713de55a7ae52744d737ef3c0296cace5bdd3cf3137078ac898c96770fde", "target_scope": "Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri\u00ae Multi-Cancer Early Detection Blood Test to Employer Plans Priority Health, a leading Michigan health plan, has partnered with GRAIL to offer the Galleri multi-cancer early detection blood test to its self-insured employer groups, making it the first in Michigan to do so.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": 0.7343, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 28.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAIL, INC. (GRAL) SHAREHOLDER ALERT Bernstein Liebhard LLP", "summary": "Bernstein Liebhard LLP has issued a shareholder alert reminding investors of GRAIL, Inc. (NASDAQ: GRAL) about an upcoming August 4, 2026 deadline for a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, leading to artificially inflated stock prices and significant losses for investors. Investors who purchased shares during this period and suffered losses are encouraged to act promptly.", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328545/0/en/grail-inc-gral-shareholder-alert-bernstein-liebhard-llp-reminds-grail-inc-investors-of-upcoming-deadline.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/16/3328545/0/en/grail-inc-gral-shareholder-alert-bernstein-liebhard-llp-reminds-grail-inc-investors-of-upcoming-deadline.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-16T13:10:14", "published_display": "16 Jul 2026 13:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "436869c9bc36b8bb4d5b74d48b1075190db9ff8370baafb4e1cbb2b2fc53bb99", "target_scope": "GRAIL, INC. (GRAL) SHAREHOLDER ALERT Bernstein Liebhard LLP Bernstein Liebhard LLP has issued a shareholder alert reminding investors of GRAIL, Inc. (NASDAQ: GRAL) about an upcoming August 4, 2026 deadline for a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, leading to artificially inflated stock prices and significant losses for investors.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.671, "provider_directional_mass": 0.4193, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 18, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024567, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 6.0, "age_days": 28.5, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) and its officers. The lawsuit alleges that GRAIL made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial between May 13, 2025, and February 19, 2026. Investors with substantial losses are encouraged to come forward by August 4, 2026, to potentially lead the class action.", "url": "https://www.natlawreview.com/press-releases/gral-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-grail-0", "source_link": "https://www.natlawreview.com/press-releases/gral-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-grail-0", "source_link_is_lookup": false, "source_name": "The National Law Review", "published_at": "2026-07-16T10:10:14", "published_display": "16 Jul 2026 10:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["The National Law Review"], "source_kind": "publisher", "story_key": "3f727af92b72b6071602b1008a7650819f46496783711fada570c020458d064d", "target_scope": "Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) and its officers. The lawsuit alleges that GRAIL made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial between May 13, 2025, and February 19, 2026.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.65, "provider_directional_mass": 0.6483, "relevance_score": 1.0, "company_focus": 0.86, "company_focus_pct": 86, "company_focus_label": "Company discussed", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 21, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.016734, "evidence_share": 0.6, "evidence_share_display": "0.6", "freshness_pct": 5.9, "age_days": 28.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP has announced a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL) for alleged misrepresentations concerning its NHS-Galleri trial. The lawsuit claims that the trial's three-year design was insufficient to achieve its primary endpoint of reducing late-stage cancers, leading to a significant stock price drop. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and incurred losses may be eligible to join the class action.", "url": "https://www.morningstar.com/news/pr-newswire/20260715ny04361/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit-investors-with-losses-may-contact-levi-korsinsky", "source_link": "https://www.morningstar.com/news/pr-newswire/20260715ny04361/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit-investors-with-losses-may-contact-levi-korsinsky", "source_link_is_lookup": false, "source_name": "Morningstar", "published_at": "2026-07-15T13:39:47", "published_display": "15 Jul 2026 13:39", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL", "GRAL.ARCHIVE"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["Morningstar"], "source_kind": "publisher", "story_key": "294c383d3612896f8653d6db0838516f6e7c48d6c8c21d717da56a6a5ec88c97", "target_scope": "GRAL Shareholder Alert: Grail, Inc. Levi & Korsinsky, LLP has announced a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL) for alleged misrepresentations concerning its NHS-Galleri trial.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.8, "provider_directional_mass": 0.4148, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 13, "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.034599, "evidence_share": 1.3, "evidence_share_display": "1.3", "freshness_pct": 5.4, "age_days": 29.5, "influence_label": "Low", "duplicate_count": 2, "topics": ["Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "$GRAL Investor Loss Alert: GRAIL, Inc. Investors may have been Misled after Channel Stuffing Claims Lead to 50% Stock Drop \u2013 Contact BFA Law if You Lost Money", "summary": "A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud after its stock dropped 50%. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which failed to meet its primary endpoint of reducing late-stage cancers. Investors who suffered losses are encouraged to contact Bleichmar Fonti & Auld LLP by August 4, 2026, to discuss their legal options.", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327542/0/en/gral-investor-loss-alert-grail-inc-investors-may-have-been-misled-after-channel-stuffing-claims-lead-to-50-stock-drop-contact-bfa-law-if-you-lost-money.html", "source_link": "https://www.globenewswire.com/news-release/2026/07/15/3327542/0/en/gral-investor-loss-alert-grail-inc-investors-may-have-been-misled-after-channel-stuffing-claims-lead-to-50-stock-drop-contact-bfa-law-if-you-lost-money.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-07-15T06:17:00", "published_display": "15 Jul 2026 06:17", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["GRAL"], "target_provider_symbol": "GRAL", "cross_listing": false, "source_names": ["GlobeNewswire"], "source_kind": "press_release", "story_key": "5417a672f99adf854d2d7358f8881ba84a8bfde60d8955d584c6c2c81842b681", "target_scope": "$GRAL Investor Loss Alert: GRAIL, Inc. A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud after its stock dropped 50%. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which failed to meet its primary endpoint of reducing late-stage cancers.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.835, "provider_directional_mass": 0.7455, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.25, "sentiment": "negative", "sentiment_pct": 20, "tone_signals": ["Failed To Meet", "Legal victory", "Legal or regulatory risk", "Negative market reaction"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.026039, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 5.2, "age_days": 29.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Finance", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}], "industry": [], "sector": []}, "total_fetched": 56, "total_unique": 56, "total_relevant": 56, "pipeline_health": {"eodhd": {"status": "healthy", "calls_used": 15, "configured": true, "last_error": "", "rate_limit": 1200, "call_budget": 10000, "requests_made": 3, "newest_seen_at": "2026-08-14T00:01:00+00:00", "rate_remaining": 1199, "budget_used_pct": 0.1, "last_success_at": "2026-08-14T00:11:21.968300+00:00", "mapped_mentions": 3883, "unmapped_mentions": 1810}, "status": "partial", "raw_articles": 87, "eodhd_articles": 0, "unique_stories": 57, "direct_evidence": 56, "provider_counts": {"eodhd": 0, "alphavantage": 76}, "provider_errors": {}, "archive_articles": 2, "current_evidence": 56, "relevant_stories": 56, "duplicates_removed": 30, "durable_story_count": 56, "providers_attempted": 2, "durable_collected_at": "2026-08-14T00:12:09.809742+00:00", "durable_evidence_used": true, "providers_with_results": 1, "matched_archive_stories": 56, "provider_rejected_counts": {"eodhd": 0, "alphavantage": 21}, "provider_relevant_counts": {"eodhd": 0, "alphavantage": 55}, "durable_newest_article_at": "2026-08-08T18:40:29+00:00"}, "sentiment_summary": {"positive": 1, "negative": 45, "neutral": 10, "score": 27, "raw_score": 19, "total": 56, "evidence_count": 56, "effective_articles": 30.81, "information_mass": 2.694, "direct_story_count": 56, "direct_source_count": 17, "industry_story_count": 0, "sector_story_count": 0, "story_count": 56, "source_count": 17, "source_concentration": 0.3394, "direct_share": 100, "dispersion": 10, "confidence": 55, "evidence_status": "measured", "score_version": "evidence-v9", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-08T18:40:29+00:00", "label": "Cautious news tone", "tone": "negative"}, "classifier": {"primary_event": "regulatory", "primary_label": "Regulatory and legal", "confidence": 87, "events": [{"event": "regulatory", "label": "Regulatory and legal", "weight": 27.78, "count": 42}, {"event": "general", "label": "Market update", "weight": 3.71, "count": 6}, {"event": "earnings", "label": "Earnings", "weight": 3.6, "count": 6}, {"event": "deals", "label": "Deals and strategy", "weight": 0.6, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.6, "count": 1}], "positive_events": 1, "negative_events": 45, "pipeline": {"eodhd": {"status": "healthy", "calls_used": 15, "configured": true, "last_error": "", "rate_limit": 1200, "call_budget": 10000, "requests_made": 3, "newest_seen_at": "2026-08-14T00:01:00+00:00", "rate_remaining": 1199, "budget_used_pct": 0.1, "last_success_at": "2026-08-14T00:11:21.968300+00:00", "mapped_mentions": 3883, "unmapped_mentions": 1810}, "status": "partial", "raw_articles": 87, "eodhd_articles": 0, "unique_stories": 57, "direct_evidence": 56, "provider_counts": {"eodhd": 0, "alphavantage": 76}, "provider_errors": {}, "archive_articles": 2, "current_evidence": 56, "relevant_stories": 56, "duplicates_removed": 30, "durable_story_count": 56, "providers_attempted": 2, "durable_collected_at": "2026-08-14T00:12:09.809742+00:00", "durable_evidence_used": true, "providers_with_results": 1, "matched_archive_stories": 56, "provider_rejected_counts": {"eodhd": 0, "alphavantage": 21}, "provider_relevant_counts": {"eodhd": 0, "alphavantage": 55}, "durable_newest_article_at": "2026-08-08T18:40:29+00:00"}}, "market_context": {"has_market_context": true, "latest_close": 69.48, "latest_week": "2026-08-07", "one_week_move": 1.3, "four_week_move": -3.5, "twelve_week_move": 16.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.602794, "market_dynamics_buy_signal": false, "relative_strength": -11.202675, "fair_value_gap": 51.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.6667, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.3% over one week, -3.5% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Bad news being absorbed", "tone": "positive", "classification": "negative_absorbed", "summary": "Cautious headlines are being absorbed by price, which can signal underlying demand.", "confidence": 77, "badges": ["Caution agrees with inactive trend"], "opportunities": [], "risks": ["Negative tone is aligned with an inactive trend backdrop."], "event_label": "Regulatory and legal", "sentiment_word": "cautious"}, "charts": {"sources": [{"label": "GlobeNewswire", "count": 18}, {"label": "PR Newswire", "count": 7}, {"label": "TradingView", "count": 5}, {"label": "Stock Titan", "count": 5}, {"label": "Morningstar", "count": 3}, {"label": "The National Law Review", "count": 3}, {"label": "ACCESS Newswire", "count": 2}, {"label": "TMX Newsfile", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Regulatory and legal", "count": 42}, {"label": "Earnings", "count": 6}, {"label": "Market update", "count": 6}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "27/100", "tone": "negative", "text": "Cautious news tone"}, {"label": "Evidence confidence", "value": "55/100", "tone": "neutral", "text": "30.81 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Bad news being absorbed", "tone": "positive", "text": "Cautious headlines are being absorbed by price, which can signal underlying demand."}, {"label": "Primary event", "value": "Regulatory and legal", "tone": "negative", "text": "87/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "10/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.3% over one week, -3.5% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "GRAIL Inc Revenue Breakdown \u2013 LSX:A40F8M"}], "updated_at": "2026-08-14T00:12:09.809742+00:00", "detail_intelligence": {"headline": "Cautious news tone", "summary": "The score uses 56 current company stories from 17 publishers.", "status": "measured", "metrics": [{"label": "News score", "value": 27, "display": "27", "tone": "negative", "note": "Cautious news tone"}, {"label": "Confidence", "value": 55, "display": "55", "tone": "neutral", "note": "building confidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "56 company stories"}, {"label": "Story agreement", "value": 90, "display": "90", "tone": "positive", "note": "10/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 54, "note": "2.694 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "17 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 8, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 90, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 66, "note": "less reliance on one publisher"}], "freshness": 8, "source_independence": 66, "timeline": [{"date": "2026-07-16", "label": "16 Jul", "count": 8, "score": 16, "tone": "negative", "x": 42.0, "y": 196.9, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-07-17", "label": "17 Jul", "count": 2, "score": 20, "tone": "negative", "x": 73.6, "y": 189.6, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-18", "label": "18 Jul", "count": 1, "score": 33, "tone": "negative", "x": 105.2, "y": 165.9, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-07-19", "label": "19 Jul", "count": 1, "score": 15, "tone": "negative", "x": 136.8, "y": 198.7, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-07-20", "label": "20 Jul", "count": 3, "score": 15, "tone": "negative", "x": 168.3, "y": 198.7, "volume_height": 19.5, "volume_y": 246.5}, {"date": "2026-07-21", "label": "21 Jul", "count": 5, "score": 17, "tone": "negative", "x": 199.9, "y": 195.1, "volume_height": 32.5, "volume_y": 233.5}, {"date": "2026-07-22", "label": "22 Jul", "count": 2, "score": 16, "tone": "negative", "x": 231.5, "y": 196.9, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-23", "label": "23 Jul", "count": 3, "score": 16, "tone": "negative", "x": 263.1, "y": 196.9, "volume_height": 19.5, "volume_y": 246.5}, {"date": "2026-07-24", "label": "24 Jul", "count": 7, "score": 24, "tone": "negative", "x": 294.7, "y": 182.3, "volume_height": 45.5, "volume_y": 220.5}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 4, "score": 20, "tone": "negative", "x": 389.4, "y": 189.6, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 4, "score": 36, "tone": "negative", "x": 421.0, "y": 160.5, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 4, "score": 16, "tone": "negative", "x": 452.6, "y": 196.9, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 4, "score": 20, "tone": "negative", "x": 484.2, "y": 189.6, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 1, "score": 10, "tone": "negative", "x": 515.8, "y": 207.8, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 3, "score": 16, "tone": "negative", "x": 642.1, "y": 196.9, "volume_height": 19.5, "volume_y": 246.5}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 0, "score": null, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 0, "score": null, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 0, "score": null, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-14", "label": "14 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "42.0,196.9 73.6,189.6 105.2,165.9 136.8,198.7 168.3,198.7 199.9,195.1 231.5,196.9 263.1,196.9 294.7,182.3 389.4,189.6 421.0,160.5 452.6,196.9 484.2,189.6 515.8,207.8 642.1,196.9 768.5,135.0", "timeline_has_signal": true, "timeline_start": "16 Jul", "timeline_mid": "31 Jul", "timeline_end": "14 Aug", "momentum": {"label": "Cooling", "tone": "neutral", "recent_score": null, "prior_score": 50, "delta": null, "recent_count": 0, "prior_count": 2, "volume_delta": -2, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 50, "delta": null, "latest_count": 0, "baseline_count": 2, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 0, "share": 0}, {"label": "4 to 7 days", "count": 2, "share": 4}, {"label": "8 to 14 days", "count": 4, "share": 7}, {"label": "15 to 21 days", "count": 23, "share": 41}, {"label": "22 to 30 days", "count": 27, "share": 48}], "source_profile": [{"label": "GlobeNewswire", "count": 18, "share": 32, "score": 18, "tone": "negative"}, {"label": "PR Newswire", "count": 7, "share": 12, "score": 14, "tone": "negative"}, {"label": "TradingView", "count": 5, "share": 9, "score": 33, "tone": "negative"}, {"label": "Stock Titan", "count": 5, "share": 9, "score": 54, "tone": "neutral"}, {"label": "Morningstar", "count": 3, "share": 5, "score": 14, "tone": "negative"}, {"label": "The National Law Review", "count": 3, "share": 5, "score": 15, "tone": "negative"}, {"label": "TMX Newsfile", "count": 2, "share": 4, "score": 13, "tone": "negative"}], "event_profile": [{"label": "Regulatory and legal", "count": 42, "share": 75, "score": 17, "tone": "negative"}, {"label": "Market update", "count": 6, "share": 11, "score": 49, "tone": "neutral"}, {"label": "Earnings", "count": 6, "share": 11, "score": 50, "tone": "neutral"}, {"label": "Guidance", "count": 1, "share": 2, "score": 37, "tone": "negative"}, {"label": "Deals and strategy", "count": 1, "share": 2, "score": 57, "tone": "neutral"}], "topics": [{"label": "Life Sciences", "count": 53, "share": 95}, {"label": "Finance", "count": 48, "share": 86}, {"label": "Financial Markets", "count": 17, "share": 30}, {"label": "Earnings", "count": 10, "share": 18}], "supporting": [{"label": "Direct evidence", "text": "56 current stories are mapped specifically to GRAL."}, {"label": "Source breadth", "text": "The score uses 17 publishers rather than depending on one outlet."}, {"label": "Story agreement", "text": "The current stories agree at 90/100."}, {"label": "Price response", "text": "Cautious headlines are being absorbed by price, which can signal underlying demand."}], "tempering": [], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "GRAIL Inc Revenue Breakdown \u2013 LSX:A40F8M", "summary": "GRAIL Inc (LSX:A40F8M) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top-performing \"Screening\" segment, an increase from 104.93 million EUR in the previous year. The United States was the largest geographical contributor, accounting for 116.72 million EUR in revenue.", "url": "https://www.tradingview.com/symbols/LSX-A40F8M/financials-segments", "source_link": "https://www.tradingview.com/symbols/LSX-A40F8M/financials-segments", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-08T18:40:29", "published_display": "08 Aug 2026 18:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.046282, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 48.2, "age_days": 5.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, "article_count": 56, "updated_at": "2026-08-14T00:12:09.809742+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 55.8, "label": "13 Feb 2026", "close": 97.5, "index": 100.0}, {"x": 78.4, "y": 184.7, "label": "20 Feb 2026", "close": 50.21, "index": 51.5}, {"x": 114.9, "y": 176.5, "label": "27 Feb 2026", "close": 53.23, "index": 54.6}, {"x": 151.3, "y": 184.7, "label": "06 Mar 2026", "close": 50.23, "index": 51.5}, {"x": 187.7, "y": 204.2, "label": "13 Mar 2026", "close": 43.06, "index": 44.2}, {"x": 224.2, "y": 193.9, "label": "20 Mar 2026", "close": 46.84, "index": 48.0}, {"x": 260.6, "y": 189.4, "label": "27 Mar 2026", "close": 48.49, "index": 49.7}, {"x": 297.0, "y": 171.7, "label": "03 Apr 2026", "close": 54.99, "index": 56.4}, {"x": 333.5, "y": 197.2, "label": "10 Apr 2026", "close": 45.63, "index": 46.8}, {"x": 369.9, "y": 180.6, "label": "17 Apr 2026", "close": 51.71, "index": 53.0}, {"x": 406.3, "y": 173.2, "label": "24 Apr 2026", "close": 54.42, "index": 55.8}, {"x": 442.8, "y": 174.2, "label": "01 May 2026", "close": 54.06, "index": 55.4}, {"x": 479.2, "y": 153.6, "label": "08 May 2026", "close": 61.64, "index": 63.2}, {"x": 515.6, "y": 159.0, "label": "15 May 2026", "close": 59.65, "index": 61.2}, {"x": 552.0, "y": 138.4, "label": "22 May 2026", "close": 67.19, "index": 68.9}, {"x": 588.5, "y": 126.2, "label": "29 May 2026", "close": 71.68, "index": 73.5}, {"x": 624.9, "y": 158.1, "label": "05 Jun 2026", "close": 59.98, "index": 61.5}, {"x": 661.3, "y": 158.4, "label": "12 Jun 2026", "close": 59.85, "index": 61.4}, {"x": 697.8, "y": 147.8, "label": "19 Jun 2026", "close": 63.74, "index": 65.4}, {"x": 734.2, "y": 141.9, "label": "26 Jun 2026", "close": 65.92, "index": 67.6}, {"x": 770.6, "y": 133.2, "label": "03 Jul 2026", "close": 69.11, "index": 70.9}, {"x": 807.1, "y": 125.3, "label": "10 Jul 2026", "close": 72.0, "index": 73.8}, {"x": 843.5, "y": 123.6, "label": "17 Jul 2026", "close": 72.62, "index": 74.5}, {"x": 879.9, "y": 136.7, "label": "24 Jul 2026", "close": 67.84, "index": 69.6}, {"x": 916.4, "y": 134.7, "label": "31 Jul 2026", "close": 68.56, "index": 70.3}, {"x": 952.8, "y": 132.2, "label": "07 Aug 2026", "close": 69.48, "index": 71.3}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 22, "stories": 4, "close": 65.92, "price_change": 3.4, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 47, "tone": "neutral", "raw_score": 38, "confidence": 30, "stories": 8, "close": 69.11, "price_change": 4.8, "x": 775.8, "y": 135.5, "show_label": true, "label_y": 125.5}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 44, "confidence": 25, "stories": 12, "close": 72.0, "price_change": 4.2, "x": 812.3, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 27, "tone": "negative", "raw_score": 20, "confidence": 64, "stories": 26, "close": 72.62, "price_change": 0.9, "x": 848.7, "y": 172.3, "show_label": true, "label_y": 162.3}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 23, "tone": "negative", "raw_score": 19, "confidence": 76, "stories": 46, "close": 67.84, "price_change": -6.6, "x": 885.1, "y": 179.7, "show_label": true, "label_y": 169.7}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 24, "tone": "negative", "raw_score": 20, "confidence": 74, "stories": 60, "close": 68.56, "price_change": 1.1, "x": 921.6, "y": 177.8, "show_label": true, "label_y": 167.8}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 25, "tone": "negative", "raw_score": 19, "confidence": 63, "stories": 57, "close": 69.48, "price_change": 1.3, "x": 958.0, "y": 176.0, "show_label": true, "label_y": 166.0}], "price_path": "42.0,55.8 78.4,184.7 114.9,176.5 151.3,184.7 187.7,204.2 224.2,193.9 260.6,189.4 297.0,171.7 333.5,197.2 369.9,180.6 406.3,173.2 442.8,174.2 479.2,153.6 515.6,159.0 552.0,138.4 588.5,126.2 624.9,158.1 661.3,158.4 697.8,147.8 734.2,141.9 770.6,133.2 807.1,125.3 843.5,123.6 879.9,136.7 916.4,134.7 952.8,132.2", "sentiment_path": "739.4,130.0 775.8,135.5 812.3,131.8 848.7,172.3 885.1,179.7 921.6,177.8 958.0,176.0", "score_version": "evidence-v9", "price_change": -28.7, "sentiment_change": -25, "recent_pairs": [{"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 25, "tone": "negative", "raw_score": 19, "confidence": 63, "stories": 57, "close": 69.48, "price_change": 1.3, "x": 958.0, "y": 176.0, "show_label": true, "label_y": 166.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 24, "tone": "negative", "raw_score": 20, "confidence": 74, "stories": 60, "close": 68.56, "price_change": 1.1, "x": 921.6, "y": 177.8, "show_label": true, "label_y": 167.8}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 23, "tone": "negative", "raw_score": 19, "confidence": 76, "stories": 46, "close": 67.84, "price_change": -6.6, "x": 885.1, "y": 179.7, "show_label": true, "label_y": 169.7}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 27, "tone": "negative", "raw_score": 20, "confidence": 64, "stories": 26, "close": 72.62, "price_change": 0.9, "x": 848.7, "y": 172.3, "show_label": true, "label_y": 162.3}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 44, "confidence": 25, "stories": 12, "close": 72.0, "price_change": 4.2, "x": 812.3, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 47, "tone": "neutral", "raw_score": 38, "confidence": 30, "stories": 8, "close": 69.11, "price_change": 4.8, "x": 775.8, "y": 135.5, "show_label": true, "label_y": 125.5}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 22, "stories": 4, "close": 65.92, "price_change": 3.4, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 69.48, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug", "live_score_version": "evidence-v9", "comparable_to_live": true}, "sentiment_history": [{"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 3, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": -2, "score_change_display": "-2", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 6, "articles": 8, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "07 Jul 23:59", "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "08 Jul 23:59", "short_label": "08 Jul", "collected_at": "2026-07-08T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "12 Jul 23:59", "short_label": "12 Jul", "collected_at": "2026-07-12T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 35, "delta": -15, "score_change": -13, "score_change_display": "-13", "confidence_change": 15, "article_change": 2, "tone": "negative", "height": 30, "articles": 16, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "16 Jul 23:59", "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score": 28, "delta": -22, "score_change": -7, "score_change_display": "-7", "confidence_change": 19, "article_change": 8, "tone": "negative", "height": 44, "articles": 24, "confidence": 62, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 27, "delta": -23, "score_change": -1, "score_change_display": "-1", "confidence_change": 2, "article_change": 2, "tone": "negative", "height": 46, "articles": 26, "confidence": 64, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 28, "delta": -22, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "negative", "height": 44, "articles": 27, "confidence": 62, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "19 Jul 23:59", "short_label": "19 Jul", "collected_at": "2026-07-19T23:59:59.999999+00:00", "score": 28, "delta": -22, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "negative", "height": 44, "articles": 28, "confidence": 61, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": -3, "score_change_display": "-3", "confidence_change": 6, "article_change": 4, "tone": "negative", "height": 50, "articles": 32, "confidence": 67, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 5, "tone": "negative", "height": 52, "articles": 37, "confidence": 71, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 23, "delta": -27, "score_change": -1, "score_change_display": "-1", "confidence_change": 2, "article_change": 1, "tone": "negative", "height": 54, "articles": 38, "confidence": 73, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 22, "delta": -28, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 1, "tone": "negative", "height": 56, "articles": 39, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 23, "delta": -27, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": 7, "tone": "negative", "height": 54, "articles": 46, "confidence": 76, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 3, "tone": "negative", "height": 52, "articles": 49, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 4, "tone": "negative", "height": 50, "articles": 53, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 3, "tone": "negative", "height": 50, "articles": 56, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 3, "tone": "negative", "height": 50, "articles": 59, "confidence": 75, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 1, "tone": "negative", "height": 52, "articles": 60, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "negative", "height": 52, "articles": 59, "confidence": 70, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 26, "delta": -24, "score_change": 2, "score_change_display": "+2", "confidence_change": -9, "article_change": 0, "tone": "negative", "height": 48, "articles": 59, "confidence": 61, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "14 Aug 00:59", "short_label": "14 Aug", "collected_at": "2026-08-14T00:59:03.807542+00:00", "score": 29, "delta": -21, "score_change": 3, "score_change_display": "+3", "confidence_change": -14, "article_change": -2, "tone": "negative", "height": 42, "articles": 57, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v9", "live_version": "evidence-v9", "comparable_to_live": true, "reconstructed": true, "observations": 31, "span_label": "52 days", "first_score": 50, "latest_score": 29, "net_change": -21, "net_change_display": "-21", "direction": "Weakening", "high_score": 50, "low_score": 22, "latest_confidence": 47, "confidence_change": 19, "latest_articles": 57, "article_change": 56, "latest_label": "14 Aug 00:59", "latest_evidence_label": "Measured", "chart_rows": [{"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 42.0, "y": 135.0}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 3, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 72.5, "y": 135.0}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 103.1, "y": 135.0}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 133.6, "y": 135.0}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 164.1, "y": 136.8}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 194.7, "y": 136.8}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": -2, "score_change_display": "-2", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 6, "articles": 8, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 225.2, "y": 140.5}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 255.7, "y": 138.6}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 286.3, "y": 138.6}, {"label": "07 Jul 23:59", "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 316.8, "y": 136.8}, {"label": "08 Jul 23:59", "short_label": "08 Jul", "collected_at": "2026-07-08T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 347.3, "y": 136.8}, {"label": "12 Jul 23:59", "short_label": "12 Jul", "collected_at": "2026-07-12T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 377.9, "y": 138.6}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 408.4, "y": 138.6}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 35, "delta": -15, "score_change": -13, "score_change_display": "-13", "confidence_change": 15, "article_change": 2, "tone": "negative", "height": 30, "articles": 16, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 438.9, "y": 162.3}, {"label": "16 Jul 23:59", "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score": 28, "delta": -22, "score_change": -7, "score_change_display": "-7", "confidence_change": 19, "article_change": 8, "tone": "negative", "height": 44, "articles": 24, "confidence": 62, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 469.5, "y": 175.0}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 27, "delta": -23, "score_change": -1, "score_change_display": "-1", "confidence_change": 2, "article_change": 2, "tone": "negative", "height": 46, "articles": 26, "confidence": 64, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 500.0, "y": 176.9}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 28, "delta": -22, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "negative", "height": 44, "articles": 27, "confidence": 62, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 530.5, "y": 175.0}, {"label": "19 Jul 23:59", "short_label": "19 Jul", "collected_at": "2026-07-19T23:59:59.999999+00:00", "score": 28, "delta": -22, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "negative", "height": 44, "articles": 28, "confidence": 61, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 561.1, "y": 175.0}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": -3, "score_change_display": "-3", "confidence_change": 6, "article_change": 4, "tone": "negative", "height": 50, "articles": 32, "confidence": 67, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 591.6, "y": 180.5}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 5, "tone": "negative", "height": 52, "articles": 37, "confidence": 71, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 622.1, "y": 182.3}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 23, "delta": -27, "score_change": -1, "score_change_display": "-1", "confidence_change": 2, "article_change": 1, "tone": "negative", "height": 54, "articles": 38, "confidence": 73, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 652.7, "y": 184.1}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 22, "delta": -28, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 1, "tone": "negative", "height": 56, "articles": 39, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 683.2, "y": 186.0}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 23, "delta": -27, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": 7, "tone": "negative", "height": 54, "articles": 46, "confidence": 76, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 713.7, "y": 184.1}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 3, "tone": "negative", "height": 52, "articles": 49, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 744.3, "y": 182.3}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 4, "tone": "negative", "height": 50, "articles": 53, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 774.8, "y": 180.5}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 3, "tone": "negative", "height": 50, "articles": 56, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 805.3, "y": 180.5}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 3, "tone": "negative", "height": 50, "articles": 59, "confidence": 75, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 835.9, "y": 180.5}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 1, "tone": "negative", "height": 52, "articles": 60, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 866.4, "y": 182.3}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "negative", "height": 52, "articles": 59, "confidence": 70, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 896.9, "y": 182.3}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 26, "delta": -24, "score_change": 2, "score_change_display": "+2", "confidence_change": -9, "article_change": 0, "tone": "negative", "height": 48, "articles": 59, "confidence": 61, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 927.5, "y": 178.7}, {"label": "14 Aug 00:59", "short_label": "14 Aug", "collected_at": "2026-08-14T00:59:03.807542+00:00", "score": 29, "delta": -21, "score_change": 3, "score_change_display": "+3", "confidence_change": -14, "article_change": -2, "tone": "negative", "height": 42, "articles": 57, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 958.0, "y": 173.2}], "chart_points": "42.0,135.0 72.5,135.0 103.1,135.0 133.6,135.0 164.1,136.8 194.7,136.8 225.2,140.5 255.7,138.6 286.3,138.6 316.8,136.8 347.3,136.8 377.9,138.6 408.4,138.6 438.9,162.3 469.5,175.0 500.0,176.9 530.5,175.0 561.1,175.0 591.6,180.5 622.1,182.3 652.7,184.1 683.2,186.0 713.7,184.1 744.3,182.3 774.8,180.5 805.3,180.5 835.9,180.5 866.4,182.3 896.9,182.3 927.5,178.7 958.0,173.2", "changes": [{"label": "14 Aug 00:59", "short_label": "14 Aug", "collected_at": "2026-08-14T00:59:03.807542+00:00", "score": 29, "delta": -21, "score_change": 3, "score_change_display": "+3", "confidence_change": -14, "article_change": -2, "tone": "negative", "height": 42, "articles": 57, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 26, "delta": -24, "score_change": 2, "score_change_display": "+2", "confidence_change": -9, "article_change": 0, "tone": "negative", "height": 48, "articles": 59, "confidence": 61, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "negative", "height": 52, "articles": 59, "confidence": 70, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 1, "tone": "negative", "height": 52, "articles": 60, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 3, "tone": "negative", "height": 50, "articles": 59, "confidence": 75, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 3, "tone": "negative", "height": 50, "articles": 56, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 25, "delta": -25, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 4, "tone": "negative", "height": 50, "articles": 53, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 24, "delta": -26, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 3, "tone": "negative", "height": 52, "articles": 49, "confidence": 74, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}